Ischemia-reperfusion injury in human liver transplantation : mechanisms and effects on graft function by Ilmakunnas, Minna
Ischemia – reperfusion injury in human liver transplantation
Mechanisms and effects on graft function
Supervisors
Professor Krister Höckerstedt
Transplantation and Liver Surgery Clinic 
Department of Surgery
Helsinki University Central Hospital
University of Helsinki
Helsinki, Finland
MD, PhD Eero Pesonen
Department of Anesthesiology and Intensive Care Medicine










Hospital for Children and Adolescents 













Transplantation and Liver Surgery Clinic, Department of Surgery
Department of Bacteriology and Immunology, Haartman-Institute
Department of Anesthesiology and Intensive Care Medicine
Helsinki University Central Hospital
Faculty of Medicine, University of Helsinki
Ischemia – reperfusion injury in human liver transplantation
Mechanisms and effects on graft function
MINNA ILMAKUNNAS
Academic dissertation
To be presented, with the permission of the Faculty of Medicine, University of Helsinki, 
for public examination in the Faltin hall, Surgical Hospital, Kasarmikatu 11–13, Helsinki, 




Abstract  .............................................................................................................. 6
Original publications ...................................................................................... 7
Abbreviations .................................................................................................... 8
Introduction .................................................................................................... 10
Review of literature ....................................................................................... 12
 LIVER TRANSPLANTATION  ......................................................................... 12
  Indications  .............................................................................................. 12
  Organ allocation ...................................................................................... 12
  Organ donors ........................................................................................... 13
  Surgery .................................................................................................... 14
  Immunosuppression ................................................................................ 16
  Outcome  ................................................................................................. 16
 DONOR INFLAMMATORY RESPONSE .......................................................... 18
 LIVER ISCHEMIA-REPERFUSION INJURY .................................................... 19
  Ischemia................................................................................................... 19
  Reperfusion ............................................................................................. 20
  “No reflow” ischemia ............................................................................... 20
  Innate immunity ...................................................................................... 21
  Kupffer cells ............................................................................................. 21
  Neutrophils .............................................................................................. 23
  Lymphocytes ............................................................................................ 26
  Soluble mediators .................................................................................... 26
  Graft function .......................................................................................... 29
 PROTEIN C – ACTIVATED PROTEIN C PATHWAY AND INFLAMMATION .. 30
Aims of the study ........................................................................................... 33
Patients and methods ................................................................................... 34
 PATIENTS AND GENERAL STUDY DESIGN ................................................... 34
 CLINICAL ASSESSMENT ................................................................................ 37
  Donors ..................................................................................................... 37
  Recipients ................................................................................................ 37
5
 RESEARCH SAMPLES ..................................................................................... 37
  Blood samples .......................................................................................... 37
  Liver biopsies ........................................................................................... 39
 LABORATORY METHODS ............................................................................. 39
  Cellular markers CD11b and L-selectin ................................................... 39
  Soluble intercellular adhesion molecule-1 ................................................ 40
  Tumor necrosis factor-α ........................................................................... 40
  Interleukin-6 and -8 ................................................................................. 40
  High mobility group box 1 protein .......................................................... 40
  Protein C and activated protein C ............................................................ 41
 STATISTICAL ANALYSIS ................................................................................. 42
Results ............................................................................................................... 43
 PATIENT OUTCOME ..................................................................................... 43
 DONOR INFLAMMATORY RESPONSE .......................................................... 44
 INFLAMMATORY RESPONSE DURING LIVER TRANSPLANTATION ........... 45
  Systemic inflammation ............................................................................. 45
  Hepatic inflammation .............................................................................. 47
  Graft function .......................................................................................... 49
 PROTEIN C – ACTIVATED PROTEIN C PATHWAY 
 IN LIVER TRANSPLANTATION ...................................................................... 50
Discussion ........................................................................................................ 52
 METHODOLOGY ........................................................................................... 52
 DONOR INFLAMMATORY RESPONSE .......................................................... 53
 INFLAMMATORY RESPONSE DURING LIVER TRANSPLANTATION ........... 54
  Systemic inflammation ............................................................................. 54
  Hepatic inflammation .............................................................................. 55
  Graft function .......................................................................................... 56
 PROTEIN C – ACTIVATED PROTEIN C PATHWAY
 IN LIVER TRANSPLANTATION ..................................................................... 57






Liver transplantation is an established therapy for both acute and chronic liver failure. 
Despite excellent long-term outcome, graft dysfunction remains a problem affecting 
up to 15-30% of the recipients. The etiology of dysfunction is multifactorial, with 
ischemia-reperfusion injury regarded as one of the most important contributors. 
This thesis focuses on the inflammatory response during graft procurement and 
reperfusion in liver transplantation in adults. Activation of protein C was examined as 
a potential endogenous anti-inflammatory mechanism. The effects of inflammatory 
responses on graft function and outcome were investigated. 
Seventy adult patients undergoing liver transplantation in Helsinki University Cen-
tral Hospital, and 50 multiorgan donors, were studied. Blood samples from the portal 
and the hepatic veins were drawn before graft procurement and at several time points 
during graft reperfusion to assess changes within the liver. Liver biopsies were taken 
before graft preservation and after reperfusion. Neutrophil and monocyte CD11b and 
L-selectin expression were analysed by flow cytometry. Plasma TNF-α, IL-6, IL-8, 
sICAM-1, and HMGB1 were determined by ELISA and Western-blotting. HMGB1 
immunohistochemistry was performed on liver tissue specimens. Plasma protein C 
and activated protein C were determined by an enzyme-capture assay. 
Hepatic IL-8 release during graft procurement was associated with subsequent 
graft dysfunction, biliary in particular, in the recipient. Biliary marker levels increased 
only 5–7 days after transplantation. Thus, donor inflammatory response appears to 
influence recipient liver function with relatively long-lasting effects. 
Hepatic phagocyte activation and sequestration, with concomitant HMGB1 re-
lease, occurred during reperfusion. Neither phagocyte activation nor plasma cytokines 
correlated with postoperative graft function. Thus, activation of the inflammatory 
responses within the liver during reperfusion may be of minor clinical significance. 
However, HMGB1 was released from hepatocytes and were also correlated with post-
operative transaminase levels. Accordingly, HMGB1 appears to be a marker of hepa-
tocellular injury.
During reperfusion, marked hepatic protein C uptake occurred without APC re-
lease from the graft. Protein C uptake correlated with decreased hepatic phagocyte 
activation. The results likely reflected intrahepatic APC production and consumption 
in anticoagulant and/or anti-inflammatory activity.
In human liver transplantation, hepatic inflammatory responses in the donor, but 
not those occurring during graft reperfusion in the recipient, appear to be associated 
with graft dysfunction in the recipient. Activation of protein C may attenuate hepatic 
inflammatory responses during reperfusion. 
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ALF, acute liver failure
ALP, alkaline phosphatase
ALT, alanine aminotransferase
AP-1, activator protein-1 
APC, activated protein C
AST, aspartate aminotransferase
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BMI, body mass index
CD, cluster of differentiation
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ELTR, European liver transplant registry
EPCR, endothelial protein C receptor
FACS, fluorescence-activated cell sorting
FITC, fluorescein isothiocyanate
GGT, γ-glutamyl transferase
HAT, hepatic artery thrombosis
HBV, hepatitis B virus 
HCC, hepatocellular carcinoma
HCV, hepatitis C virus
HIV, human immunodeficiency virus
HMGB1, high mobility group box 1 
HSPs, heat shock proteins
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MCP-1, monocyte chemotactic protein-1
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NADPH, nicotinamide adenine dinucleotide phosphate
NF-κB, nuclear factor kappa B
NK cells, natural killer cells
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NO, nitric oxide
PAF, platelet-activating factor
PAMP, pathogen-associated molecular pattern
PAR-1, protease activated receptor-1 
PBC, primary biliary cirrhosis
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PSGL-1, P-selectin glycoprotein ligand-1
PT, prothrombin time
RAGE, receptor for advanced glycation end-products
RFU, relative fluorescence unit
ROS, reactive oxygen species




TNF-α, tumor necrosis factor- α
TLR, toll-like receptor
UNOS, United Network for Organ Sharing
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During the past 40 years, liver transplantation has evolved from a highly experimental 
procedure into the treatment of choice for acute liver failure (ALF), end-stage liver 
disease, and liver tumors of limited size and number. The first human liver transplan-
tation was performed in 1963 in Denver, USA, by Thomas Starzl (Starzl et al. 1963). 
In Europe it was pioneered by Sir Roy Calne, who in 1968 performed the first liver 
transplantation in Cambridge, UK. Finland set up a liver transplantation program 
in 1982; the first Nordic country to do so. The number of transplanted patients has 
since increased rapidly. To date, over 75,000 livers have been transplanted in Europe 
(European Liver Transplant Registry, ELTR, 2007), with 725 livers transplanted into 
658 patients (by July 2008) in Helsinki University Central Hospital (HUCH), the 
only transplant centre in Finland. 
Patient outcome has improved along with advances in patient selection, organ 
preservation, surgical techniques, perioperative anesthetic and intensive care, infection 
control, and immunosuppression. Currently in Europe, the overall 1-year survival is 
82% and 10-year survival 61%, with the best outcome in recipients with chronic liver 
disease (ELTR 2007). During the first postoperative year, recipients who had ALF 
have the worst outcome, whereas long-term survival is unfavorable for those who had 
malignancy (ELTR 2007). From 1982 to the present time, the overall 1-year survival 
in Finland is 89% and 10-year survival 72%, and currently the results for ALF are 
equal to those for chronic liver disease (Isoniemi, personal communication). As the 
survival has improved, emphasis has shifted to detection and treatment of long-term 
complications, such as late allograft dysfunction, and medical problems related to im-
munosuppression. However, graft function early after transplantation still continues 
to influence significantly the long-term outcome.
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Several events at the time of transplantation can influence initial graft function and 
thereby the outcome. The liver may suffer damage already in the donor by prepreser-
vation injury. Brain death and the following period of intensive care induce alterations 
in hemodynamic and metabolic regulation, and also inflammatory responses. These 
factors contribute to liver viability (Pratschke et al. 1999, Pratschke et al. 2004). Cold 
preservation of the graft leads to impaired cellular metabolism, non-parenchymal cell 
injury, and disturbances in microcirculation. During implantation into the recipient, 
the graft is exposed to rewarming ischemia, a period deleterious to hepatocytes. When 
the liver blood flow is restored, the graft sustains ischemia-reperfusion (I/R) injury, 
characterized by the activation of the Kupffer cells, neutrophil recruitment into the 
liver, tissue destruction by reactive oxygen species (ROS) and proteases, and also the 
amplification of the inflammatory response by cytokines (Strasberg et al. 2005). 
In a clinical setting, the inflammatory responses and their effects on graft function 
remain poorly defined in both the liver donor and recipient. This study explored the 
hepatic inflammatory responses during graft procurement and also reperfusion. In 
addition, endogenous anti-inflammatory mechanisms, specifically the protein C – ac-
tivated protein C (APC) pathway, were examined. Finally, the effect of these events on 






Currently, indications for liver transplantation are increasing in number, whereas ab-
solute contraindications are becoming infrequent. Any patient with a failing liver, and 
who is expected to survive perioperatively and adhere to postoperative medical care, 
should be considered for transplantation. The main indications are cirrhosis due to 
various reasons, cholestatic diseases, metabolic or genetic disorders, vascular abnor-
malities, ALF, and primary malignant liver diseases (Mehrabi et al. 2008). In Europe, 
the most common indications in adult patients include cirrhosis 58%, cancers 12%, 
and cholestatic diseases 11% (including primary biliary cirrhosis, PBC; and primary 
sclerosing cholangitis, PSC) (ELTR 2007). In Finland, the respective figures are 22%, 
9%, and 33%. In other European countries, virus related cirrhosis is the foremost 
cause for transplantation, whereas in Finland only 3% of transplantations are due 
to hepatitis B (HBV) or C (HCV). In contrast, in Finland the most common single 
indication is ALF (19%), followed by PBC (17%) and PSC (14%), and alcoholic 
cirrhosis (9%) (Isoniemi, personal communication). In children, biliary atresia is the 
most prevalent disease leading to liver transplantation in Finland.
The contraindications include a lack of patient compliance, continuous alcohol 
and substance abuse, untreatable advanced cardiovascular or pulmonary disease, ext-
rahepatic malignancy, sepsis, and multiorgan failure (Strasberg et al. 1994, Markmann 
et al. 2001, Mehrabi et al. 2008) Although there is no formal age limit, older patients 
have reduced survival (Collins et al. 2000, ELTR 2007), and patients over 70 years 
of age are transplanted only in selected cases. Until recently, HIV infection was con-
sidered a contraindication, but improved survival related to antiretroviral therapy has 
also made HIV patients eligible for liver transplantation (Verdonk et al. 2007).
Organ allocation
In Finland, liver allocation is based on recipient medical urgency, ABO blood group 
compatibility, time on the waiting list, weight compatibility (estimated donor liver 
size), and donor–recipient age compatibility. There are no uniform allocation cri-
teria in Europe, although the Model for End-Stage Liver Disease (MELD) is used 
increasingly (Mehrabi et al. 2008). Based on international normalized ratio (INR), 
and serum creatinine and bilirubin levels, MELD is a scoring system by which the 
patient mortality risk determines organ allocation, instead of the time on the waiting 
list (Kamath and Kim 2007). 
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Organ donors 
In Finland, all liver grafts are obtained from brain dead multiorgan donors. Grafts are 
harvested in donor hospitals by an organ procurement team, which includes an an-
esthesiologist, from HUCH. Donor care in the intensive care unit and during organ 
retrieval is standardized according to national guidelines (Ohjeet elintenluovuttajan 
hoidosta ja elinten talteenotosta, HUCH, Department of Surgery 2004).
Donor selection. An ideal donor is under 50 years old with stable hemodynam-
ics, normal liver and kidney function, and without malignancy or systemic infection 
(Fondevila and Ghobrial 2005, Mehrabi et al. 2008). As there is a continuously grow-
ing shortage of suitable donor organs, livers from compromised “extended criteria” 
donors are commonly accepted, with an increased risk of initial graft dysfunction 
(Strasberg et al. 1994, Busuttil and Tanaka 2003). Donor specific predictors of graft 
dysfunction include age, graft macrovesicular steatosis >30%, prolonged intensive 
care, hypotension with high dose vasoactive support, and acid-base and electrolyte 
imbalances, specifically peak sodium over 155 mmol/l (Mor et al. 1992, Markmann et 
al. 2001, Briceno et al. 2002, Cuende et al. 2005, Nissen and Colquhoun 2005). Im-
portantly, all these factors have a cumulative deleterious effect on the graft (Pokorny et 
al. 2005, Fischer-Fröhlich and Lauchart 2006). Absolute contraindications for organ 
donation remain active malignancy and transmissible infections, such as HIV, HBV, 
HCV, and sepsis (Mehrabi et al. 2008).
Alternative graft sources. To overcome the organ shortage, livers can, in addition to 
the brain dead donors, be obtained from living donors or non-heart-beating donors 
(donation after cardiac death). Further, the liver from a cadaveric donor can be split 
into a right and left liver graft to be transplanted into two recipients. However, the 
use of these alternative grafts is associated, in addition to the risks to the living donor, 
with increased rate of primary dysfunction, postoperative surgical complications, and 
recipient mortality (Deshpande and Heaton 2006, Foster et al. 2007).
Donor medical management. The main objective in the donor’s care is to maintain 
an optimal physiological environment for the organs until their procurement (Ohjeet 
elintenluovuttajan hoidosta ja elinten talteenotosta, HUCH, Department of Surgery 
2004). Systolic blood pressure is kept above 100 mmHg with colloid and hypotonic 
(0.45%) saline infusions. If unresponsive to volume resuscitation, then vasoactive 
drugs, dopamine (2–10 μg/kg/min) as the primary choice, are initiated to treat donor 
hypotension. Diuresis is maintained 0.5 ml/kg/h at a minimum with fluids, and des-
mopressin (0.5–1 μg) administered for polyuria. Target plasma sodium level is below 
145 mmol/l. Ventilator settings are adjusted to achieve normoxia and normocapnia. 




Liver Procurement. After dissection of the graft and preparation of the vessels for 
cannulation, anticoagulation is induced by 25,000 U of heparin. After cross-clamping 
and cannulation of the aorta or the common iliac artery, and superior mesenteric vein, 
the liver is flushed in situ first with 1000 ml of +4°C Ringer solution via the portal 
vein, and then perfused with 30 ml/kg (body weight) of +4°C University of Wiscon-
sin (UW) solution via the portal vein and approximately 50 ml/kg via the aorta. The 
graft is then explanted and preserved at +4°C in UW solution. 
Surgery
The technique of liver transplantation varies to some extent between transplant cen-
tres. In general, the procedure involves three phases; dissection of the recipient native 
liver, the anhepatic phase, and finally orthotopic implantation and reperfusion of the 
graft. 
Hepatectomy. The aim during the dissection of the native liver is to preserve enough 
length in the hilar structures (hepatic artery, portal vein, biliary tract) for the implan-
tation and revascularizarion of the new liver. Most of the bleeding during surgery 
occurs during this period due to impaired blood clotting, portal hypertension and 
collaterals in cirrhotic patients, and the presence of adhesions in patients with previ-
ous abdominal surgery (Eghtesad et al. 2005). 
Anhepatic phase. At the beginning of the anhepatic phase, the hepatic artery, portal 
vein, and both supra- and infrahepatic caval vein, are crossclamped. The native liver 
is then removed. During the anhepatic period, complete occlusion of both portal and 
inferior caval veins can result in considerable hemodynamic instability particularly 
in patients without porto-systemic collaterals. This can be overcome by veno-venous 
bypass or caval vein sparing (Piggyback) surgery. Both techniques are associated with 
reduced blood loss, improved hemodynamic stability, and protection of renal venous 
outflow and function (Eghtesad et al. 2005). In veno-venous bypass, blood is diverted 
from the portal and inferior caval veins (via femoral vein) to the superior caval vein 
(to axillary or internal jugular vein) through the extracorporeal circuit. The veno-
venous bypass approach is not used in HUCH. Veno-venous bypass can be avoided 
by preservation of the recipient’s retrohepatic caval vein (Piggyback technique). In 
the conventional Piggyback technique (Tsakis et al. 1989, Eghtesad et al. 2005), the 
liver is dissected separated from the retrohepatic caval vein, and a cuff formed from 
the hepatic veins is anastomosed to the donor suprahepatic caval vein end-to-side. 
In HUCH, a modified Piggyback (Belghiti et al. 1992) is performed with cavo-caval 
anastomosis side-to-side. In this thesis, Piggyback was used in two patients (included 
in analysis, studies III,IV) with significant hemodynamic instability during tentative 
inferior caval vein crossclamping. 
Graft implantation. Supra- and infrahepatic caval vein anastomoses are performed 
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in an end-to-end fashion, followed by portal anastomosis. Next, hepatic arterial anas-
tomosis is completed, the site of anastomosis depending on the arterial anatomy. Fi-
nally, the biliary tract is reconstructed. Graft cholecystectomy is performed before 
reconstruction of the bile ducts, which is performed as duct-to-duct anastomosis 
without the T-tube (Koivusalo et al. 1996, Scatton et al. 2001). In patients with PSC, 
the biliary tract is reconstructed by choledochojejunostomy to a Roux-en-Y intestinal 
limb (Eghtesad et al. 2005).
Ischemia and reperfusion. Graft cold preservation begins at explantation from the 
donor and ends when the recipient portal circulation is restored. The cold ischemic 
time (CIT), is kept as short as possible, preferably under 8 h (Furukawa et al. 1991, 
Briceno et al. 2002). During implantation, the graft is ambiently exposed to body 
temperature, a period of rewarming ischemia. The anhepatic time (time from clamp-
ing of the native hepatic vessels to restoration of portal circulation) reflects the du-
ration of rewarming ischemia. Graft reperfusion comprises three phases (Figure 1). 
First, the liver is rinsed with 1000 ml of Ringer solution (pH 7.4, +20ºC) via the 
portal vein, followed by flushing with 400 ml of portal venous blood. Second, these 
fluids are washed out through the untied infrahepatic caval vein anastomosis (caval ef-
fluent, wasted except for research samples). Third, portal and suprahepatic caval veins 
are declamped, and the liver is connected to the systemic circulation. Fourth, caval 
blood flow is restored after the completion of infrahepatic caval anastomosis and dec-
lamping, either concomitantly with or a few minutes after portal declamping. Finally, 
the arterial circulation is typically restored 45 minutes after initial reperfusion.
Review of literature
Figure 1. Phases of liver reperfusion.
1. Initial reperfusion (graft flushing with portal blood) is followed by the suprahepatic caval 
vein (SVC) declamping. During initial reperfusion, blood samples were drawn from the portal 
vein and caval effluent.
2. Declamping of the infrahepatic caval vein (IVC) and portal vein (PV). Blood samples were 
drawn at 5 to 10 min after portal vein declamping from the portal and hepatic veins. 
3. Declamping of the hepatic artery (HA). Blood samples were drawn at 10 min after hepatic 
artery declamping from the portal and hepatic veins.
16
Immunosuppression
A calcineurin inhibitor, either cyclosporine or tacrolimus, is indicated as the the basis 
for immunosuppression. Both calcineurin inhibitors are associated with significant 
adverse effects such as nephrotoxicity, hypertension, dyslipidemia, and neurotoxicity. 
Both cyclosporine and in particular tacrolimus are also diabetogenic (Sethi and Strav-
itz 2007, Mehrabi et al. 2008). Corticosteroids are an integral part of the immuno-
suppressive regimen. They have dose-dependent side-effects, including hypertension, 
dyslipidemia, diabetes, and osteoporosis. Therefore tapering of the dose is usually 
attempted during the first year after transplantation (Verdonk et al. 2007, Mehrabi et 
al. 2008). In addition to calcineurin inhibitors and corticosteroids, antimetabolites, 
either azathioprine or mycofenolate mofetil (MMF), are frequently used. When ad-
ministered concomitantly with antimetabolites, the calcineurin inhibitor dose can 
be reduced to limit the side-effects (Verdonk et al. 2007). In HUCH, liver recipients 
generally receive a standard triple immunosuppression with cyclosporine, MMF (aza-
thioprine until 2004), and methylprednisolone. 
Outcome
Initial graft function. Within the first days postoperation, a patient with an optimally 
functioning liver graft demonstrates stable hemodynamics, decreasing liver enzyme 
levels, improving coagulation profile, preserved renal function, and an absence of en-
cephalopathy.
 Graft dysfunction varies from a potentially reversible dysfunction to a failure 
necessitating urgent retransplantation. Graft dysfunction can be divided into pri-
mary dysfunction (PDF) and primary non-function (PNF) (Strasberg et al. 1994). 
Although uniform definitions for PDF are lacking, alanine aminotransferase (ALT) 
and/or aspartate aminotransferase (AST) levels over 1500 U/l within the first three 
days are usually considered to indicate PDF (Strasberg et al. 1994). PDF is reversible 
with improving graft condition, whereas recipients with PNF progressively deteriorate 
(Nissen and Colquhoun 2005). PNF manifests as rapidly increasing transaminase lev-
els resulting from hepatocellular necrosis, an absence of bile production, coagulopa-
thy, lactic acidocis, and multiorgan failure, in recipients with patent vascular anasto-
moses. The United Network for Organ Sharing (UNOS) proposed criteria for PNF 
as being: AST over 5000 U/l, and INR over 3.0 or the presence of acidocis (pH <7.3 
or lactate level >2×normal) within 10 days of transplantation (Nissen and Colquhoun 
2005). It is worth noting that ELTR defines PDF as a graft loss or patient death due 
to impaired liver function in excess of 7 days, and PNF as those same events within 7 
days after transplantation. In international series, the incidence of PDF is estimated 
to be 15–30% and PNF 6% (Mehrabi et al. 2008). In contrast, the incidence on PNF 
is only 0.6% in Finland (Isoniemi, personal communication).  
Review of literature
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The risk factors for graft dysfunction, in addition to the extended donor criteria, 
include CIT >12 h (Furukawa et al. 1991, Briceno et al. 2002, Burroughs et al. 2006), 
a prolonged rewarming ischemia (Strasberg et al. 1994), and increased blood product 
requirements during transplantation (Markmann et al. 2003). Further, such recipient 
conditions as ALF, high MELD score, and a degree of renal dysfunction before trans-
plantation predispose to PDF and PNF (Nissen and Colquhoun 2005). 
Surgical complications. Vascular and biliary complications are fairly common and 
significantly contribute to the outcome. Hepatic artery thrombosis (HAT) is the most 
common vascular complication with an incidence of up to 5%, and often necessitates 
retransplantation. Risk factors for HAT are long CIT and surgical problems with 
anastomosis (Settmacher et al. 2000). HAT can occur either early (within 30 days of 
transplantation) or late, and usually presents with elevated transaminases, followed by 
biliary strictures, cholangitis, and septic infections (Drazan et al. 1996, Settmacher et 
al. 2000). Postoperative venous complications, such as portal vein stenosis and throm-
bosis, or hepatic outflow obstruction, are relatively rare. 
The incidence of biliary complications, the most typical of which are biliary leak-
age and biliary tract strictures, is 10-15% (Eghtesad et al. 2005, Mehrabi et al. 2008). 
Anastomotic leakage occurs early, whereas strictures appear later after transplanta-
tion. Strictures can be divided into anastomotic and non-anastomotic. Anastomotic 
strictures are usually due to surgical difficulties and fibrous healing of the anastomosis 
(Verdonk et al. 2006). The most common reason for non-anastomotic strictures, for 
both hilar and intrahepatic ducts, is ischemia of the biliary epithelium caused by im-
paired arterial blood flow, HAT, or I/R injury (Sanchez-Urdazpal et al. 1992, Buis et 
al. 2006). Elevations in bilirubin levels and canalicular enzyme levels and cholangitis 
episodes are characteristic of biliary strictures (Eghtesad et al. 2005).
Long term outcome. During the period of this study (registry data over the 2000–
2005 period), the patient survival at 1-year was 94% and at 5-years 87% (Isoniemi, 
personal communication). Late complications can be either related to graft function, 
or metabolic derangements. Acute rejection is characterized by lymphocytic infiltra-
tion in the portal tracts, and is typically diagnosed within 30 days. However, it can 
occur any time after transplantation. The incidence of acute rejection varies from 20% 
to 60% (Fisher et al. 1995, Wiesner et al. 1998, Pfitzmann et al. 2008). In contrast, 
chronic rejection, which is characterized by a loss of bile ducts and cholestasis is a 
rare phenomenon. The most common cause of late graft dysfunction is the recur-
rence of the original disease, commonly HCC, HBV, HCV, and the autoimmune 
diseases PBC, PSC, and autoimmune hepatitis (Wiesner and Menon 2001). Com-
mon medical causes for late morbidity and mortality include renal dysfunction and 
cardiovascular diseases. Their risk factors include hypertension, hyperlipidemia, and 
post-transplant diabetes (Sethi and Stravitz 2007). Further, de novo malignancy after 
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transplantation is relatively common (Haagsma et al. 2001). All these complications 
can be attributed mainly to the immunosuppressive agents.
DONOR INFLAMMATORY RESPONSE 
Brain death alters cardiovascular and neuroendocrine functions. The severe physiolog-
ical derangements contribute to the viability of organs to be transplanted. Brain stem 
herniation leads to a catecholamine surge. This “autonomic storm” is characterized by 
extreme vasoconstriction and, despite concomitantly elevated blood pressure, tissue 
hypoperfusion. Subsequently, a loss of autonomic tone leads to impaired vascular au-
toregulation and hypotension, potentially worsening the tissue ischemia. Regarding 
neuroendocrine functions, hypothalamic-pituitary dysfunction can lead to endocrine 
failure. In addition, an antidiuretic hormone deficiency leads to hypovolemia and 
electrolyte disturbances. The loss of normal thyroid function can result in mitochon-
drial dysfunction and impaired cellular energy production, whereas glucocorticoid 
deficiency debilitates normal control of inflammation (Novitzky 1997, Pratschke et 
al. 1999).
Brain death elicits both systemic and organ-specific inflammatory responses. Al-
though little understood, activation of these responses is multifactorial. Hemodynamic 
instability leads to periods of tissue ischemia and reperfusion in the donor (Pratschke 
et al. 2004). Catecholamine release during the autonomic storm may also directly 
activate intracellular apoptotic and proinflammatory pathways (Novitzky 1997). The 
loss of neural regulatory mechanisms, including both neuroendocrine stress response 
and autonomic nervous system functions, also contributes to the uncontrolled activa-
tion of innate immune responses (Sternberg 2006). 
Systemic inflammation is manifested as elevated plasma levels of cytokines tumor 
necrosis factor-α (TNF-α) and interleukin-6 and -8 (IL-6, IL-8) in human brain dead 
organ donors (Palombo et al. 1994, Strangl et al. 2001, Weiss et al. 2007, Murugan et 
al. 2008), whereas inflammatory responses at the end organ level are best defined in 
experimental models. 
Induction of brain death leads to Kupffer cell activation in the liver (Olinga et al. 
2005) and also enhanced hepatic TNF-α, IL-1, and IL-6 expression (Takada et al. 
1998, Okamoto et al. 2000). Upregulation of adhesion molecule expression on the 
sinusoidal endothelium is followed by hepatic neutrophil and monocyte infiltration 
(van der Hoeven et al. 1999, van der Hoeven et al. 2000, Okamoto et al. 2000). Ir-
respective of the systemic hemodynamic status, liver microcirculation becomes im-
paired after brain death (Okamoto et al. 2000, Golling et al. 2003). These events 
directly contribute to reduced graft survival from brain dead donors. Cold preserva-
tion and reperfusion of the graft further potentiate the adverse effects of brain death, 
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resulting in greater hepatocellular damage and further reduced survival (van der Ho-
even et al. 2001).
LIVER ISCHEMIA-REPERFUSION INJURY
The liver receives 70% of its perfusion from the splanchnic area via the portal vein, 
and the remaining 30% from the hepatic artery. However, for oxygen delivery the 
hepatic artery accounts for 50%. Both portal and arterial blood ultimately drain into 
the sinusoids, where liver cells are exposed to nutritive and toxic substances, foreign 
antigens, microbial components, and inflammatory mediators. Hepatocytes, consti-
tuting approximately 70% of the liver mass, are responsible for the metabolic and 
detoxification functions of the liver. In addition to the hepatocytes, the liver consists 
of non-parenchymal cells. These include sinusoidal endothelial cells, Kupffer cells, 
stellate cells, and lymphocytes. Non-parenchymal cells stimulate hepatocyte prolif-
eration and control extracellular matrix turnover, regulate sinusoidal blood flow, and 
participate in immune responses. 
Ischemia
Liver I/R injury can occur in several situations, such as low-flow states (e.g. distrib-
utive or hypovolemic shock), during liver resection with inflow occlusion (Pringle 
maneuver), and in liver transplantation. The liver can be subjected to either warm 
(normothermic) or cold (+4ºC) ischemia. In the clinical setting, warm ischemia is 
fairly common, whereas cold ischemia occurs almost exclusively during preservation 
of the graft for transplantation.
Ischemia is a state where inadequate or interrupted blood flow leads to intracel-
lular oxygen depletion and a subsequent decrease in oxidative phosphorylation and 
adenosine triphosphate (ATP) generation. ATP depletion leads to a loss of cell mem-
brane integrity, followed by intracellular swelling and derangement in cellular cal-
cium homeostasis. Increased cytosolic calcium activates intracellular phospholipases 
and proteases, leading to cell membrane disruption and activation of apoptotic and 
necrotic pathways (Nieuwenhuijs et al. 2006). 
Warm ischemia. Warm ischemia is associated with profound mitochondrial dys-
function (Townsend et al. 1987). Warm ischemia primarily affects hepatocytes, with 
extensive liver enzyme release from necrotic cells (Ikeda et al. 1992). Most of the stud-
ies on hepatic I/R injury used experimental models of warm segmental or total hepatic 
ischemia with relatively long ischemic times lasting for up to 90 minutes. Such a set-
ting does not directly apply to I/R injury in liver transplantation.
Cold ischemia. As compared to warm ischemia, cold ischemia is associated with a 
reduced oxidative phosphorylation and an increased anaerobic metabolism (Church-
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ill et al. 1994, Gillispie et al. 2007). Cold ischemia mainly affects non-parenchymal 
cells, particularly sinusoidal endothelial cells, Kupffer cells, and biliary epithelial cells 
(McKeown et al. 1988, Ikeda et al. 1992, Noack et al. 1993). Although hepatocytes 
appear relatively resistant to cold ischemia, Vajdová et al. (2000) have demonstrated 
that cold preservation sensitizes hepatocytes to rewarming ischemia, which in turn 
contributes to the loss of hepatocyte viability. 
Reperfusion
While ischemia primes the cells for damage, the actual injury usually manifests after 
the restoration of blood flow and tissue oxygenation. The key mechanism of tissue 
injury is the intense and excessive inflammatory response to reperfusion. Although 
initially considered a condition mediated by innate immune responses, I/R injury 
also triggers adaptative immunity and liver regeneration, thus influencing late graft 
function.
The effects of reperfusion seem to depend on the type of ischemia. After warm 
ischemia, I/R injury occurs in a biphasic manner; in that an initial phase of Kupffer 
cell activation is followed by hepatic neutrophil infiltration after several hours have 
elapsed (Jaeschke et al. 1990). In contrast, in response to cold ischemia, hepatic neu-
trophil sequestration occurs early after reperfusion and concomitantly with Kupffer 
cell activation (Shibuya et al. 1997, Kataoka et al. 2002). 
In general, ROS generation and complement activation occur early during reper-
fusion. In addition to direct cytotoxic effects, these mediators prime, activate, and 
recruit neutrophils into the liver. Activated Kupffer cells express cytokines and chem-
okines, thereby leading to further neutrophil activation and recruitment. Neutrophils 
inflict tissue damage on the liver through the generation of ROS and the release of 
proteolytic enzymes. 
“No reflow” ischemia
Despite the restoration of circulation, the liver may still suffer from hypoxia. Mi-
crocirculatory disturbances related to endothelial I/R injury can cause uneven tissue 
perfusion, resulting in “no-reflow” ischemia. Kupffer cells and sinusoidal endothelial 
cells express tissue factor (TF) after reperfusion, thereby activating intravascular co-
agulation (Kobayashi et al. 1998). The activation of coagulation cascades lead to fibrin 
and platelet deposition within the sinusoids during reperfusion (Kakizoe et al. 1990, 
Cywes et al. 1993). In addition to thrombus formation, sinusoid plugging can be due 
to adherent leukocytes and sloughed endothelial cells (McKeown et al. 1988, Vollmar 
et al. 1994). Further, endothelial injury is associated with increased production of va-
soconstrictor molecules (platelet-activating factor, PAF; endothelin-1, thromboxane 
A2,) and a decrease in the vasodilator molecules (nitric oxide, NO; prostacyclin), lead-
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ing to vascular dysregulation (Clemens et al. 1997). Accordingly, Puhl et al. (2005) 
have suggested that both mechanical obstruction and vasoconstriction impair hepatic 
microcirculation, thereby causing hepatocellular damage even after reperfusion.
Innate immunity
The innate immune system provides the first line of defense against pathogens and 
non-infectious tissue injury, and initiates adaptative immune responses. Non-paren-
chymal cells, particularly the Kupffer cells and sinusoidal endothelial cells are impor-
tant innate immune effectors in the liver. 
Pathogen recognition or tissue damage initiates acute inflammatory responses. In-
nate immune cells detect specific microbial structures, pathogen-associated molecular 
patterns (PAMPs), such as lipopolysaccharide (LPS) and peptidoglycan. Moreover, 
endogenous substances released from distressed cells, so called alarmins, activate in-
nate immunity responses. Alarmins include, among others, the high mobility group 
box 1 (HMGB1) protein (Park et al. 2004), heat shock proteins (HSP) (Vabulas et 
al. 2002), and extracellular matrix components released by proteases at sites of tissue 
damage (Johnson et al. 2002). Collectively, PAMPs and alarmins are called damage-
associated molecular patterns (DAMPs).
Pattern-recognition molecules and receptors (PRRs) recognize DAMPs. PRRs can 
be divided into three categories: secreted, membrane-bound, and phagocytic. Hepa-
tocytes secrete PRRs, or acute phase proteins, in response to cytokine stimulation. 
Secreted PRRs include complement proteins and C-reactive protein (CRP), that ac-
tivate the complement and opsonize microbes for phagocytosis (Gao et al. 2008). 
Membrane-bound PRRs, such as Toll-like receptors (TLRs), are expressed in all cell 
types in the liver (Schwabe et al. 2006). TLR signalling leads to the expression of cy-
tokines, cellular adhesion molecules, and acute phase proteins through the activation 
of transcription factor nuclear factor kappa B (NF-κB) (Medzhitov et al. 1997, Muzio 
et al. 1998). Phagocytic PRRs, expressed by Kupffer cells, the sinusoidal endothelium, 
and neutrophils, directly bind to opsonized microbes and macromolecules on the cell 
surface, followed by phagocytosis. Phagocytic PRRs include complement, scavenger, 
mannose, and Fc -receptors (Gao et al. 2008).
Kupffer cells
Monocytes in the blood are relatively inactive. However, upon tissue migration, mono-
cytes transform into actively phagocytosing tissue macrophages. Kupffer cells, the liv-
er residing macrophages, constitute over 80% of tissue macrophages in the body and 
over 30% of non-parenchymal cells in the liver (Bilzer et al. 2006). The Kupffer cells 
reside within the sinusoids, partly adherent on the endothelial surface. The Kupffer 
cells are primarily located in the periportal areas and therefore in continuous contact 
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with the portal blood from the gastrointestinal tract. These are involved in the clear-
ance of defective erythrocytes and activated neutrophils. They are also involved in the 
elimination of microbes and microbial components, such as LPS (Bilzer et al. 2006). 
In addition to directly phagocytosing microbes, Kupffer cells introduce extracellularly 
bound microbes to the neutrophils, which then ingest and kill the microbes (Gregory 
et al. 2002). Further, Kupffer cells are capable of antigen presentation through major 
histocompatibility complex (MHC) class I and II molecules (Lohse et al. 1996).
Kupffer cells (Figure 2) can be activated by the following: By DAMPs through 
TLR (Su et al. 2000), by complement factors through specific complement recep-
tors (Hinglais et al. 1989), by cell surface structures through mannose and scavenger 
receptors (Gao et al. 2008), and by cytokines through specific receptors (Hoffmann 
et al. 1994). According to Schemmer et al. (1998), simple physical manipulation of 
the liver also directly activates Kupffer cells. In human liver transplantation, Kupffer 
cells become activated already during cold ischemia and further during reperfusion 
(Carles et al. 1994).
Activated Kupffer cells promote both local and systemic inflammation after liver 
Figure 2. Kupffer cell functions.
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I/R injury by producing an array of inflammatory mediators, including cytokines, 
chemokines, ROS, NO, and bioactive lipids (Decker 1990, Wanner et al. 1996). 
These agents activate the endothelium and increase vascular permeability, activate 
neutrophils, activate lymphocytes, and induce acute-phase protein synthesis in hepa-
tocytes (Figure 2).
In an experimental setting, Kupffer cell inhibition prior to cold ischemia improves 
graft microcirculation after reperfusion, in addition to improving graft survival after 
transplantation (Kukan et al. 1997, Schemmer et al. 1998).
Neutrophils 
Polymorphonuclear neutrophils (PMNs) are the major effector cells of the innate 
immune system. Neutrophils are the most prevalent leukocytes in circulating blood, 
but are not present in tissues under normal conditions. Upon acute inflammation, 
activated neutrophils rapidly extravasate and migrate into the tissues (Figure 3). 
Granules. Neutrophil functions are dependent on controlled exocytosis of cyto-
plasmic granules. These granules are formed sequentially during neutrophil differenti-
ation from myeloblasts, and are degranulated in a reverse sequence during neutrophil 
activation. Granules can be classified as azurophilic (primary), specific (secondary), 
gelatinase (tertiary), and secretory vesicles. Azurophilic granules containing myeloper-
oxidase and serine proteases undergo only limited exocytosis and mainly fuse with the 
intracellular phagosome, thereby participating in killing and the subsequent degrada-
tion of micro-organisms and cell debris. Specific granules contain antibiotic substanc-
es such as lysozyme and lactoferrin, whereas gelatinase granules contain mainly matrix 
degrading enzymes (Faurschou and Borregaard 2003). Secretory vesicles constitute an 
important reservoir for membrane-bound receptors, such as CD11b/CD18, CD14, 
complement receptors, and also components of nicotinamide adenine dinucleotide 
Figure 3. Neutrophil adhesion cascade.
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phosphate (NADPH) oxidase. These are upregulated rapidly in the initial phases of 
neutrophil-mediated inflammatory responses (Calafat et al. 1993).
Activation. Neutrophil activation status varies from resting, to primed, and then to 
fully activated. During the priming phase, inflammatory mediators lower the thresh-
old for neutrophil activation and enhance the capacity for degranulation and that 
of ROS formation through respiratory burst (Edwards 1995, Condliffe et al. 1998). 
Several factors trigger neutrophil priming and activation. These include the macro-
phage-derived cytokines (TNF-α, IL-1β) and chemokines (IL-8), activated comple-
ment proteins (C3a, C5a), bioactive lipids (prostaglandins, PAF), and bacterial com-
ponents. Activating signals are transmitted through various neutrophil cell surface 
PRRs and specific receptors (Edwards 1995).
Extravasation. Neutrophil recruitment into sites of inflammation is an essential 
step in the innate immune response (Figure 3). Extravasation typically takes place 
in the postcapillary venules, and is mediated by three different types of cell adhesion 
molecules (Ley et al. 2007). The selectins are membrane glycoproteins that interact 
with P-selectin glycoprotein ligand-1 (PSGL-1) and other glycosylated ligands. P-se-
lectin and E-selectin are expressed by the activated endothelium, whereas L-selectin 
is present in most leukocytes. The integrins are heterodimeric proteins expressed on 
leukocytes. The key integrins in neutrophil extravasation include CD11a/CD18 and 
CD11b/CD18. The third type of adhesion molecules belong to the immunoglobu-
lin superfamily and are expressed on the activated endothelium. These molecules in-
clude intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 
(VCAM-1).
Inflammatory mediators released by activated monocytes and macrophages stimu-
late the endothelial cells to rapidly translocate P-selectin onto their luminal surfaces 
from intracellular stores. Endothelial E-selectin synthesis and ICAM-1 upregulation 
are also stimulated by TNF-α and IL-1β. Neutrophil rolling on the endothelium is 
mediated by the selectins. This interaction triggers mobilization of neutrophil secre-
tory vesicles, resulting in concomitant cell surface CD11b upregulation and L-selectin 
shedding (Kishimoto et al. 1989, Borregaard et al. 1994). Neutrophil arrest during 
rolling is triggered by chemokines and subsequently mediated by CD11b. Chemok-
ines increase CD11b affinity for ICAM-1, thus favoring strong adhesion. Integrins 
also mediate neutrophil crawling along the endothelial surface to suitable sites for 
transmigration. Transmigration occurs either through the endothelial cell junctions 
(paracellular route) or directly through endothelial cells at thin parts of the endotheli-
um (transcellular route). Diapedesis, migration through the basement membrane and 
underlying tissue, is directed along the chemotactic gradient and is facilitated by in-
tegrins and proteolytic enzymes degrading the extracellular matrix (Ley et al. 2007). 
In the liver, neutrophils can extravasate in the sinusoids or post-sinusoidal venules 
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(Vollmar et al. 1994, Fox-Robichaud and Kubes 2000). In the post-sinusoidal venules, 
neutrophils rolling, adherence, and transmigration occur as described above (Jaeschke 
and Smith 1997). However, neutrophil extravasation takes place most commonly in 
the sinusoids. The occurrence of neutrophil trapping within the sinusoids is mainly 
due to mechanical constraints, such as Kupffer cell processes, endothelial cell swelling, 
and vasoconstriction (MacPhee et al. 1992, Jaeschke and Smith 1997). Neutrophil 
adhesion onto the sinusoidal endothelial surface is independent of selectins (Wong 
et al. 1997), and despite constitutive ICAM-1 expression is mostly independent of 
ICAM-1 (Jaeschke et al. 1996). However, transmigration requires CD11b–ICAM-1 
interaction between the neutrophil and endothelium (Sakamoto et al. 1997). When 
extensive inflammatory injury to the endothelium occurs, neutrophils have direct ac-
cess to the liver parenchyma and hepatocytes expressing ICAM-1 (Jaeschke and Smith 
1997, Kobayashi et al. 2001).
The inhibition of neutrophil adhesion limits neutrophil-mediated tissue injury 
in experimental models. Although neutrophil recruitment into the liver is partly in-
dependent of selectins, soluble PSGL-1 reduces both warm and cold liver I/R injury 
(Dulkanchainun et al. 1998). Similarly, anti-ICAM-1 antibodies also attenuate both 
warm and cold liver I/R injury (Farhood et al. 1995, Nishimura et al. 1996). Moreo-
ver, anti-CD11b/CD18 antibodies are efficient in reducing hepatic neutrophil se-
questration and hepatocellular injury after warm I/R injury (Jaeschke et al. 1993).
Cell killing. Microbe or cell destruction by neutrophils is mediated through two 
principal means; ROS and proteolytic enzymes. Neutrophils phagocytose opsonized 
material, an event followed by ROS generation within the phagosome and intracel-
lular granule coalescence into the phagosome. 
Neutrophils produce ROS by the action of membrane-bound NADPH oxidase 
that catalyzes the superoxide anion (O2
.-) formation from oxygen (O2). The superox-
ide is then converted into hydrogen peroxide (H2O2) both spontaneously and cata-
lyzed by superoxide dismutase (SOD). Myeloperoxidase reacts with H2O2 to induce 
hypochloric acid (HOCl) formation. H2O2 can also be converted into toxic hydroxyl 
radicals (OH-) in the presence of metal ions. ROS induce cell damage through protein 
and DNA oxidation, subsequent degradation, and also by lipid peroxidation. Several 
different antioxidants have beneficial effects on liver I/R injury (Glantzounis et al. 
2005).
The most important proteolytic enzymes are the serine proteases and matrix met-
alloproteinases (MMPs). The serine proteases include proteinase-3, cathepsin G, and 
elastase, that are stored in the azurophilic granules in their active form. They exhibit 
proteolytic capacity against collagens and proteoglycans (Owen and Campbell 1999). 
Neutrophil gelatinase granules contain MMP-8 (collagenase) and MMP-9 (gelatinase 
B) in their inactive proforms, which undergo proteolytic activation upon exocytosis. 
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Generally, MMPs can degrade all extracellular matrix protein components (Owen 
and Campbell 1999). In addition to proteolysis, proteolytic enzymes regulate innate 
immune responses by activating macrophages (Hubbard et al. 1991), and by activat-
ing or inactivating cytokines and the cell signaling receptors (van den Steen 2000, 
Wiedow and Meyer-Hoffert 2005). Both elastase and MMP-9 inhibition has proved 
effective, in addition to I/R injury after warm liver ischemia, against I/R injury in 
experimental liver transplantation (Soejima et al. 1999, Defamie et al. 2008). 
Reperfusion in clinical liver transplantation. Hepatic neutrophil activation occurs 
early during reperfusion. This is indicated by the upregulation of CD11b expres-
sion and intracellular H2O2 production across the hepatic circulation during initial 
reperfusion. Neutrophils are sequestered into the graft concomitantly, and proteolytic 
enzymes such as elastase and MMP-9 are released from the graft (Himmelreich et al. 
1994, Thiel et al. 1998, Kiuchi et al. 1998, Pesonen et al. 2000, Upadhya and Stras-
berg 2000, Marti et al. 2004). 
Lymphocytes
Resident lymphocytes in the liver are dominated by innate immune cells, includ-
ing natural killer (NK) cells and T-cells expressing NK molecules (NKT cells). They 
predominantly reside along the portal tracts. These lymphocytes express antigen re-
ceptors of limited variability, recognize cell membrane glycoproteins and lipid com-
ponents, and exhibit rapid cytokine production and cytotoxic activity (Doherty and 
O’Farrelly 2000). 
Lymphocytes, specifically the CD4 positive T-cells, are rapidly recruited into the 
liver after reperfusion (Zwacka et al. 1997). The CD4 positive T-cells can be activated 
independently of antigen presentation by ROS, cytokines released by the Kupffer 
cells, and complement factors. These T-cells may also undergo antigen-dependent 
activation as both sinusoidal endothelial cells and hepatic dendritic cells activated 
during ischemia are capable of antigen presentation (Huang et al. 2007). In addi-
tion to initiating adaptative immune responses, T-cells enhance hepatic neutrophil 
recruitment, thereby amplifying tissue injury. In a murine warm hepatic I/R injury 
model, depletion of CD4 positive cells reduces inflammation and hepatocellular in-
jury (Zwacka et al. 1997).  
Soluble mediators 
The innate immune system induces inflammatory responses through soluble media-
tors. Cytokines are small proteins (<30 kDa) produced by various cells in response 
to pattern recognition, or stimulation by other cytokines. They induce responses in 
target cells through specific receptors, share common signal transduction cascades, 
and are involved in both the innate and adaptative immune responses. Chemoattract-
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ant cytokines (chemokines) are released early during inflammation. They recruit and 
guide inflammatory cells into the affected tissues, and activate their target cells. In 
addition to cytokines and chemokines, the complement fragments (C3a, C5a), lipid 
mediators formed from degraded membrane phospholipids (prostaglandins, leukot-
rienes, PAF), and adhesion molecules shed from the endothelium, are all engaged in 
the regulation and amplification of inflammatory responses. 
Tumor necrosis factor-α. TNF-α is derived primarily from monocytes and macro-
phages activated by DAMPs. TNF-α is expressed as a membrane bound protein that is 
enzymatically cleaved into a soluble form. Both membrane bound and soluble forms 
exhibit biological activity (Bradley 2008). TNF-α itself is short-lived (Selby et al. 
1987), though it stimulates the expression of secondary inflammatory mediators such 
as IL-6 and IL-8 and thereby propagates inflammation. In addition, TNF-α induces 
inflammatory changes in the endothelium including increased permeability, adhesion 
molecule expression, and local activation of blood coagulation cascade through TF 
expression. In the liver, TNF-α appears to promote hepatocyte proliferation during 
liver regeneration both directly and through enhanced IL-6 release from Kupffer cells 
(Bradham et al. 1998). During the reperfusion in clinical liver transplantation, TNF-
α is released from the graft (Steininger et al. 1994, Tange et al. 2001).
Interleukin-6. IL-6 is produced rapidly in response to TNF-α and IL-1β stimula-
tion mainly by macrophages and T-cells. IL-6 regulates hematopoiesis and induces 
lymphocyte proliferation and activation. It also contributes to the defense against 
infection and tissue trauma by inducing fever, adrenocorticotropic hormone release, 
and acute phase protein synthesis in the liver (Song and Kellum 2005). Although IL-
6 is generally a marker of proinflammatory response (Waage et al. 1989), it also has 
protective functions in the liver. For example, IL-6 regulates hepatic inflammatory 
response (Clavien et al. 1996), hepatocyte apoptosis (Kovalovich et al. 2001), and 
induces liver regeneration (Cressman et al. 1996, Camargo et al. 1997). 
Interleukin-8. IL-8 (also known as CXCL8) is a chemotactic cytokine (chemokine) 
expressed by virtually all nucleated cells, including hepatocytes (Thornton et al. 1990), 
though it is mainly expressed by monocytes and macrophages (Remick 2005). TNF-α 
and IL-1β induce the secretion of IL-8 early during the inflammatory response and 
unlike the other chemokines, the IL-8 response persists for days. Thus it ensures on-
going recruitment of inflammatory cells into damaged tissue (DeForge et al. 1992). 
Neutrophils are the main target for IL-8 mediated chemotaxis. IL-8 bound to the en-
dothelium (Middleton et al. 1997) and extracellular matrix (Webb et al. 1993) directs 
neutrophil migration into sites of infection and tissue damage along a chemotactic 
gradient. Further, IL-8 primes neutrophils for respiratory burst and degranulation 
(Edwards 1995). In the liver, IL-8 may also promote acute phase protein synthesis 
(Wigmore et al. 1997), and it is also released from the liver during reperfusion in clini-
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cal liver transplantation (Mueller et al. 1996, Pesonen et al. 2000).  
High mobility group box 1 protein. HMGB1 (amphoterin) is an abundant nuclear 
protein involved in DNA bending and transcription regulation in all nucleated cells 
(Lotze and Tracey 2005). Extracellular HMGB1 (Figure 4) can be released either pas-
sively from necrotic cells (Scaffidi et al. 2002) or actively secreted primarily by immune 
cells of myeloid origin (Wang et al. 1999, Lotze and Tracey 2005) and by endothelial 
cells (Mullins et al. 2004). Further, Tsung et al. (2007) reported that hepatocytes 
can secrete extracellular HMGB1 in response to ischemia. Bacterial components, cy-
tokines, and ROS are also known inducers of active HMGB1 secretion (Wang et al. 
1999, Rouhiainen et al. 2004, Tang et al. 2007).
Figure 4. Extracellular HMGB1 as a mediator of inflammation.
Extracellular HMGB1 acts as an alarmin that induces innate immune cell activa-
tion, fever, increased vascular and intestinal permeability, and hypotension. HMGB1 
exerts its effects on target cells through receptor for advanced glycation end-products 
(RAGE) and TLRs (Lotze and Tracey 2005). HMGB1 stimulates monocyte and neu-
trophil activation, in addition to the release of multiple cytokines and chemokines 
(Andersson et al. 2000, Park et al. 2003). HMGB1 also induces endothelial cell ac-
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tivation and upregulation of adhesion molecules (Fiuza et al. 2003, Treutiger et al. 
2003). It also mediates monocyte and neutrophil recruitment and migration into 
the sites of inflammation (Rouhiainen et al. 2004, Orlova et al. 2007, Palumbo et al. 
2007). 
In sepsis and endotoxemia, HMGB1 is a late inflammatory mediator: HMGB1 
release is delayed for several hours after initial TNF-α expression (Wang et al. 1999, 
Yang et al. 2004, Rouhiainen et al. 2004). Further, according to Levy et al. (2007), 
extracellular HMGB1 initiates systemic inflammation and injury at the end organ 
level after locally confined tissue injury.
In the murine model of warm hepatic I/R injury, HMGB1 acts as an early mediator 
of inflammation and organ damage. Inhibition of HMGB1 activity with neutralizing 
antibody decreases hepatocellular injury (Tsung et al. 2005a). Moreover, treatment 
with ethyl pyruvate, an antioxidant with direct inhibitory activity against HMGB1, is 
hepatoprotective in an experimental setting (Tsung et al. 2005b).
Soluble intercellular adhesion molecule-1. sICAM-1 represents a circulating form 
of ICAM-1. TNF-α and IL-1β stimulate ICAM-1 expression on and also sICAM-1 
release from the endothelium (Witkowska and Borawska 2004). In addition, sICAM-
1 originates from monocytes (Rothlein et al. 1991) and hepatocytes (Thomson et al. 
1994), among others. Generally, sICAM-1 is considered to reflect endothelial activa-
tion and damage. It is shed from the endothelial surface by the action of proteases 
(Champagne et al. 1998), but also appears on membranes of microparticles released 
from disturbed endothelial cells (Jy et al. 2002). It has been suggested that sICAM-1 
may modulate the inflammatory process by acting as a chemotactic factor, and by 
competing with membrane-bound ICAM-1 to prevent leukocyte adhesion to the en-
dothelium (Rothlein et al. 1991).
Graft function 
Hepatocellular injury. Although hepatocytes are resistant to cold ischemia, they are sen-
sitive to rewarming ischemia (Vajdová et al. 2000), and prolonged rewarming ischemia 
is also a risk factor for graft dysfunction in clinical liver transplantation (Strasberg et 
al. 1994). According to Lehmann et al. (1998), hepatocyte function can be impaired, 
even in the absence of morphological changes and microcirculatory disturbances. Re-
warming hinders the restoration of optimum hepatocyte ATP levels, thereby disturb-
ing cell volume and electrolyte homeostasis, in addition to disruptions to synthetic 
and metabolic functions. Moreover, complement activation and neutrophil sequestra-
tion within the liver during reperfusion inflict direct damage on hepatocytes (Kakizoe 
et al. 1990, Scoazec et al. 1997). During uneventful recovery, hepatocellular integrity 
and synthetic function, as assessed by transaminase and coagulation factor levels, gen-
erally normalize within two to three days after transplantation.  
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Biliary function. ATP degradation during ischemia leads to biliary epithelial mi-
crovilli dysfunction, dilatation of bile canaliculi, and decreased bile flow through 
the activation of intracellular proteases (Cutrin et al. 1996). Upon reperfusion, neu-
trophils infiltrate into the bile ducts, thus intensifying the ischemic injury (Carrasco 
et al. 1996, Busquets et al. 2001). Cholestasis and impaired secretion of hydrophobic 
bile salts can directly damage both biliary cells and hepatocytes (Sokol et al. 1995). 
Compared to that in the hepatocytes, recovery of the biliary epithelium is prolonged 
after I/R injury. Markers of biliary function (bilirubin; γ-glutamyl transferase, GGT; 
alkaline phosphatase, ALP) peak as late as 10 to 15 days after transplantation (Cutrin 
et al. 1996).
Long term outcome. In a clinical setting, liver I/R injury is generally graded accord-
ing to postoperative hepatocellular damage, as indicated by transaminase levels. A 
significant rise in transaminases is associated with an increasing incidence of acute re-
jection, PNF, 1-year patient survival, and a late recurrence of the original liver disease 
(Howard et al. 1990, Devlin et al. 1995, Rosen et al. 1998, Watt et al. 2006).
PROTEIN C – ACTIVATED PROTEIN C PATHWAY 
AND INFLAMMATION 
The protein C pathway plays a critical role in linking coagulation and inflammation. 
Protein C, which is synthesized in the liver, is a major endogenous anticoagulant. 
Protein C is converted into activated protein C (APC) on the endothelial surface by 
thrombin-thrombomodulin (TM) complex (Figure 5). This conversion is augmented 
by protein C binding to the endothelial protein C receptor (EPCR). APC exhibits 
direct anticoagulant activity by irreversible proteolytic inactivation of the coagula-
tion factors Va and VIIIa. APC also enhances fibrinolysis. In addition to maintain-
ing coagulation homeostasis, APC has anti-inflammatory properties. APC reduces 
thrombin formation and fibrin deposition, and thereby indirectly attenuates vascular 
permeability and reduces phagocyte recruitment into the sites of vascular damage. 
Furthermore, APC has direct cytoprotective properties that are independent of its 
anticoagulant effects (Mosnier et al. 2004).
When mediating cytoprotective effects, APC binds to EPCR activates protease ac-
tivated receptor 1 (PAR-1) on the cell surface (Figure 5). In addition to the endothe-
lium, both EPCR and PAR-1 are expressed in monocytes and neutrophils (Calligan et 
al. 2001, Kannan 2002, Colognato et al. 2003, Sturn et al. 2003). PAR-1 activation 
by APC results in the inhibition of inflammatory gene expression. Moreover, APC 
blocks the expression of cytokines, particularly that of TNF-α, in monocytes and also 
the endothelial cells (Grey et al. 1994, White et al. 2000, Joyce et al. 2001, Yuksel et al. 
2002, Franscini et al. 2004). According to Yamaji et al. (2005), APC also suppresses 
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ROS production in macrophages and has direct antioxidant properties through the 
inhibition of lipid peroxidation. 
The APC molecule modulates phagocyte recruitment into sites of inflammation 
(Figure 5). Although endothelial expression of several chemokines is upregulated in 
response to APC (Hooper et al. 1998, Riewald et al. 2002, Franscini et al. 2004), APC 
bound to EPCR effectively inhibits phagocyte chemotaxis (Sturn et al. 2003, Nick et 
al. 2004). Furthermore, APC down-regulates the expression of endothelial adhesion 
molecules, thereby reducing endothelial phagocyte adhesion (Joyce et al. 2001, Fran-
scini et al. 2004). A soluble form of EPCR binds to CD11b/CD18 on neutrophils, 
which may further interfere with neutrophil adherence onto the endothelium (Ku-
rosawa et al. 2000). In addition to its anti-inflammatory activity, APC maintains the 
endothelial barrier function and normal permeability under inflammatory conditions 
(Zeng et al. 2004, Feistritzer and Riewald 2005). It also inhibits endothelial cell and 
monocyte apoptosis (Cheng et al. 2003, Stephenson et al. 2006).
In vivo, APC supplementation has beneficial effects both on coagulopathy and 
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Figure 5. Cytoprotective effects of activated protein C (APC). 
Modified from Mosnier et al. 2007.
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inflammation under pulmonary inflammation and injury, and septic infections. In 
addition, APC prevents LPS induced pulmonary injury by inhibiting the inflamma-
tory responses in the lungs in both rats and humans (Murakami et al. 1996, Nick et 
al. 2004). Likewise, in experimental and human severe sepsis, APC limits inflamma-
tion (Bernard et al. 2001, Hoffmann et al. 2004) and reduces mortality (Taylor et al. 
1987, Bernard et al. 2001). Further, APC improves microcirculation in experimental 
endotoxemia (Hoffmann et al. 2004, Iba et al. 2005). Other actions of APC include 
neuroprotection and promotion of wound healing and angiogenesis (Mosnier et al. 
2007).
Exogenous APC also has anti-inflammatory effects on experimental I/R injury of 
liver (Yamaguchi et al. 1997) and kidney (Mizutani et al. 2000), among others. More-
over, APC attenuates remote organ injury after local I/R injury (Teke et al. 2008). Re-
cently, Kuriyama et al. (2008) demonstrated that APC treatment was associated with 
multiple cytoprotective effects both through anti-inflammatory and anticoagulant 
functions in an experimental model of warm hepatic I/R injury. APC decreased he-
patocellular injury and apoptosis. Further, APC attenuated neutrophil and monocyte 
activation and hepatic infiltration, in addition to hepatic TNF-α expression. Improve-
ments in microcirculation by the inhibition of coagulation and sinusoidal endothelial 
cell injury were also mediated by APC. 
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Aims of the study
The overall purpose of this thesis was to explore the inflammatory response and en-
dogenous regulatory mechanisms in clinical liver transplantation. The main emphasis 
of the research was on graft reperfusion, particularly those changes occurring in the 
transplanted liver.
The specific objectives were:
1. To evaluate the hepatic inflammatory response in the multiorgan donor at the 
time of liver procurement and its subsequent effects on early postoperative graft func-
tion and outcome (I).
2. To describe the kinetics of protein C – APC pathway both during and after 
transplantation, to explore the potential anti-inflammatory effects of protein C – APC 
pathway during graft reperfusion, and to evaluate the effect of protein C – APC path-
way on early postoperative graft function and outcome (II,III). 
3. To describe the kinetics of HMGB1 both during and after transplantation, and 
to evaluate HMGB1 in relation to early postoperative graft function (IV).
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Patients and methods
PATIENTS AND GENERAL STUDY DESIGN
Seventy adult patients undergoing liver transplantation, regardless of the indication, 
participated the studies (Table 1). In addition, blood samples were obtained from a 
total of 50 multiorgan donors (I and IV), 30 of whom were also evaluated regarding 
their clinical variables (I; Table 2). The studies were conducted in the Transplantation 
and Liver Surgery Clinic of the Surgical Hospital, HUCH. The patients were re-
cruited during the 2000-2001 period and also 2006. Laboratory samples were assayed 
in the Department of Bacteriology and Immunology, Haartman-Institute, University 
of Helsinki (I, II, and III); in the Department of Clinical Chemistry, HUCH and 
HUSLAB (I, II, and III); in the Department of Molecular and Experimental Medi-
cine, Scripps Research Institute, La Jolla, CA, USA (II and III); and in the Neuro-
science Center, University of Helsinki (IV).
Studies I, II, and III were approved by the Ethics committee in the Surgical Hos-
pital and for study IV by the Ethics committee, Department of Surgery, Hospital 
District of Helsinki and Uusimaa. Informed consent was obtained from the patients 
prior to their transplantations. For patients with significant encephalopathy, the con-
sent was obtained from their next of kin. 
Study I comprised 30 consecutive multiorgan donors in Finland and their respec-
tive liver recipients. One donor-recipient pair was excluded from the final data analy-
sis due to the recipient’s excessive perioperative bleeding of 75,000 ml. During graft 
procurement, plasma IL-6, IL-8, and sICAM-1 levels, and adhesion molecule expres-
sion in circulating neutrophils were measured across the hepatic circulation. The effect 
of hepatic inflammatory response at the time of procurement on the postoperative 
liver function and outcome were investigated. Immunosuppression consisted of cy-
closporine, azathioprine, and steroids. 
Study II comprised 10 consecutive patients, in whom plasma protein C and APC 
were measured during liver transplantation and postoperatively up to day 6. Adhesion 
molecule expression in circulating neutrophils and monocytes was also measured. Im-
munosuppression consisted of cyclosporine, azathioprine, and steroids. 
Study III comprised 50 consecutive patients, including those from study II. Three 
patients were excluded from the final data analysis. Of these, two exclusions were 
due to technically different reperfusion (portal vein and hepatic artery declamped 
simultaneuously), and one exclusion due to excessive perioperative bleeding. Plasma 
protein C and APC, and adhesion molecule expression in circulating neutrophils and 
monocytes were measured during graft reperfusion across the hepatic circulation. The 
effect of protein C activation on postoperative liver function and outcome were in-
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Table 1. Patient characteristics
I II III IV
Patients, n 30 10 47 20
Age, yrs 49 (22–64) 38 (24–61) 44 (20–64) 50 (22–66)
Sex, male/female 18/11 6/4 28/19 14/6
Acute liver failure, n (total) 5 2 8 3
nonA-E hepatitis 4 2 6 2
Toxic liver injury 1 1
Acute autoimmune hepatitis 1
Angiosarcoma 1
Chronic liver disease, n (total) 21 8 36 17
PBC 2 1 9 3
PSC 4 2 8 1
Alcoholic cirrhosis 5 2 7 4
Cryptogenic cirrhosis 2 1 3 3
Chronic rejection 2 1 2
Familial biliary cirrhosis 1 2
Idiopathic portal hypertension 1 1 1
Liver fibrosis 1 1
Chronic active hepatitis 1
Post-hepatitic cirrhosis 1
Subacute liver failure 1
NAFLD 2
Polycystic liver disease 1
Chronic autoimmune hepatitis 1
Budd-Chiari 1
Hepatitis B 1
Hepatocellular carcinoma, n (total) 3 3 *
PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; 
NAFLD, non-alcoholic fatty liver disease.
For subacute liver failure, the origin was unknown. 
* Histology revealed incidental carcinoma in 4 patients with cirrhosis.
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vestigated. Patients received either cyclosporine (n=31) or tacrolimus (n=16) based 
immunosuppression. The effect of immunosuppression was not evaluated.
Study IV comprised 20 consecutive patients, in whom plasma HMGB1, IL-6, and 
TNF-α were measured during transplantation and postoperatively up to 48 h. In ad-
dition, plasma HMGB1 was measured in the donors before organ procurement. The 
associations between HMGB1, other cytokines, and postoperative liver function were 
evaluated. The cellular HMGB1 expression was determined by immunohistochemis-
try. Patients received either cyclosporine (n=7) or tacrolimus (n=13) based immuno-
Table 2. Donor characteristics
Age (yrs) 43 (14–59)
Gender (M/F) 24/19
Body mass index (kg/m2) 23 (19–31)
History of hypertension (yes/no) 7/36




Donor cardiac arrest (yes/no) 4/39
ICU length of stay (days) 1 (0–9)
Time from BD to liver perfusion (hrs)a 10.6 (4.9–25.2)
Hypotensive events (yes/no)b 15/28
Vasoactive support (yes/no) 41/2
dopamine alone (n) 24
dopamine + other (n)c 14
norepinephrine alone (n) 3
dopamine dose (μg/kg/min) 5.9 (2.1–15.9)
Desmopressin (yes/no) 34/9
Liver graft steatosis (%)d 0 (0–80)
< 30 % (n) 36
> 30 % (n) 7
Continuous data are expressed as median (range).
BD = brain death, ICU = intensive care unit 
a Time from BD declaration to perfusion; 
b Systolic blood pressure < 90 mmHg > 15 min




suppression. As no difference in study parameters or outcome between the immuno-
suppression groups were found (data not shown), the groups were combined.
CLINICAL ASSESSMENT 
Donors
The data analysis donor variables included: gender, age, body mass index (BMI), his-
tory of hypertension, cause of brain death (trauma vs. intracranial hemorrhage, ICH), 
donor cardiac arrest, ICU length of stay (ICU stay; days), time from brain death 
diagnosis to liver graft perfusion, hypotensive events (defined as systolic blood pres-
sure <90 mmHg for >15 minutes) (Mor et al. 1992, Fernandez-Merino et al. 2003) 
during intensive care and organ procurement, and vasoactive agents used. For vasoac-
tive drugs, mean dose (μg/kg/min) over the 24 hours prior to organ procurement was 
calculated. The need for desmopressin, and plasma sodium levels were recorded. Oth-
er laboratory values measured were hemoglobin level, leukocyte counts, ALT, GGT, 
ALP, bilirubin, prothrombin time (PT), and CRP, all taken as a part of screening of 
the donors. Graft steatosis was assessed from biopsies taken prior to graft perfusion 
during procurement. Only macrovesicular steatosis was taken into account in data 
analysis (Fishbein et al. 1997).
Recipients
Perioperative variables analyzed were anhepatic time, graft CIT, and bleeding. All 
postoperative laboratory tests were performed as a part of routine clinical follow-
up. Plasma ALT, ALP, GGT, bilirubin, and PT, were measured daily during the first 
postoperative week, and the peak (the lowest for PT) values were recorded (I, III). 
The galactose elimination half-life (t½) was determined at day 7 postoperation (III). 
In studies I, II, and III, patients were followed up to one year after transplantation 
at our centre. In study IV, the follow-up period was three months. Complications 
and outcome, including biliary and vascular complications, rejection episodes, patient 
survival, and graft survival, were recorded (I, II, and III). Patient follow-up was dis-
continued at graft loss or death.
In study IV, peak ALT and INR values were measured within 72 hours of reper-
fusion, and those of bilirubin on day 7, were included in data analysis. The outcomes 
within three months were recorded.
RESEARCH SAMPLES
Blood samples
Donor. Blood samples were collected before donor surgery in study IV. In contrast, 
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blood samples were collected at the beginning of donor surgery and before perfusion 
and explantation of the liver graft in study I. The first blood sample was drawn via 
an arterial cannula. Before perfusion, samples were taken simultaneously by puncture 
from the portal and hepatic veins.
Recipient. Blood samples were collected (Figure 1): after the induction of anesthe-
sia but before surgery (II, III, and IV); immediately before the anhepatic period (II); 
immediately before reperfusion (II, III, and IV); during initial reperfusion of the graft 
with portal blood (II-IV); at 5 min (II, III) or at 10 min (IV) after portal vein dec-
lamping; and at 10 min after hepatic artery declamping (II, IV). After surgery, sam-
ples were collected on 1, 2, 4, and 6 postoperative days (II). In study IV, samples were 
collected at 8 h, 24 h, and 48 h after reperfusion. 
Before surgery and reperfusion, blood samples were drawn from the radial arte-
rial cannula. Before the anhepatic period, samples were drawn by puncture from the 
portal and hepatic veins. During initial reperfusion, samples were drawn from the 
portal vein and the inferior caval vein stump of the graft (caval effluent). After portal 
vein and hepatic artery declamping, samples were drawn from the portal and hepatic 
veins. In study IV blood samples were drawn, in addition to hepatic circulation, from 
radial arterial cannula. Postoperative samples were collected either from radial artery 
or by venipuncture. 
Sample handling. Blood samples (volume 10 ml) were drawn into pyrogen-free 
syringes. In order to minimise inflammatory activation ex vivo, samples were im-
mediately divided into aliquots into pre-cooled tubes, and these tubes were placed in 
thawing ice (+0ºC) until further handling. 
For analysis of phagocyte adhesion molecule expression (I, II, and III), a 1 ml 
quantity of the sample was transferred into a polystyrene tube (Falcon No 2054, Bec-
ton Dickinson Labware, Lincoln Park, NJ, USA) supplemented with 170 μl of pyro-
gen-free citrate (Baxter Health Care, Norfolk, England). The tube was then stored in 
thawing ice (+0ºC) until cell labelling. 
For analyses of protein C and APC (II, III), a 1.8 ml quantity of the sample was 
mixed with 0.2 ml of 0.3 mol/l benzamidine (a reversible thrombin inhibitor; Sigma-
Aldrich, St. Louis, MO, USA) in 0.109 mol/l sodiumcitrate. Within 30 minutes of 
sampling, the plasma was separated by centrifugation (at 1900 g for 15 min), and 
thereafter stored at -70ºC until analyses. 
For analyses of soluble mediators, in study I a 3 ml quantity or the whole sample 
in study IV was transferred into a sodium citrate anticoagulated tube (Vacutainer Sys-
tems Europe, Becton Dickinson, France). The plasma was separated by centrifugation 
(at 1900 g for 15 min, study I; and at 2000 g for 10 min, study IV), and thereafter 
stored at -70 to -80ºC until assayed. 
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The remaining blood was transferred into an EDTA-tube (Vacutainer) and stored 
at room temperature until analysis of leukocyte differential counts (II, III) (Advia 120, 
Bayer, Terrytown, NY, USA).
Liver biopsies
In study IV, two biopsies were obtained from each graft; the first was taken during 
liver procurement immediately before graft perfusion and the second biopsied at the 
end of liver transplantation prior to skin closure. The liver biopsies were fixed in for-
malin and then embedded in paraffin. 
LABORATORY METHODS
Cellular markers CD11b and L-selectin
Adhesion molecule expression in circulating neutrophils and monocytes were deter-
mined by flow cytometry (Repo et al. 1993). All steps of cell staining were carried out 
on thawing ice (+0ºC) with ice-cold reagents.
Cell labelling. All monoclonal antibodies were purchased from Becton Dickinson 
(Becton Dickinson Europe, Temse, Belgium). For the analyses of neutrophil CD11b 
and L-selectin (CD62L) expression, an aliquot of 25 µl of whole blood was double-
stained with saturating concentrations of anti-CD11b-phycoerythrin (PE) and anti-
CD62L-fluorescein isothiocyanate (FITC). In the analyses of monocyte CD11b and 
L-selectin expression, two 25 µl aliquots of whole blood were double stained with 
saturating concentrations of anti-CD14-FITC and anti-CD11b-PE, or anti-CD14-
PE and anti-CD62L-FITC, respectively. After staining, the samples were lysed twice 
in 1:10 diluted FACSLysing solution (Becton Dickinson) to remove contaminating 
erythrocytes. Leukocytes were then fixed with 1.35% formaldehyde in FACSFlow 
solution (Becton Dickinson), with a final concentration of 0.5%. Samples were stored 
on thawing ice (+0ºC) until flow cytometry analysis was carried out within 24 h.
Flow cytometry. A FACSort flow cytometer (Becton Dickinson) and CellQuest 
software (Becton Dickinson) were used for the acquisition and analysis of the data. 
Their light scattering properties enabled data representing 5000 neutrophils to be 
collected. Adhesion molecule expression was evaluated by creating fluorescence histo-
grams for both CD11b and L-selectin. Data for 1000 monocytes were collected from 
a gate in a side scatter/CD14 fluorescence dot plot, and fluorescence histograms were 
created for CD11b and L-selectin. Adhesion molecule expression is given in relative 




Soluble intercellular adhesion molecule-1
Plasma sICAM-1 levels were determined using Quantikine Human sICAM-1 Immu-
noassay (R&D Systems, Abington, UK), with a detection limit of 0.35 ng/ml.
Tumor necrosis factor-α
Plasma TNF-α was measured using a WEHI-13VAR cell assay (Khabar et al. 1995, 
Tange et al. 2001). Briefly, 40 000 WEHI-13VAR cells per microwell were cultured 
overnight. The incubation medium was then changed to one containing Actinomycin 
D (Sigma-Aldrich). A 100 μl quantity of the diluted plasma samples (25% and 50% 
plasma in phosphate buffered saline, PBS) or recombinant TNF-α standards (0-1000 
pg/ml, Pierce-Endogen, Rockford, IL, USA) was added to wells and cultured over-
night. After culturing in a medium containing methylthiazolyldiphenyl-tetrazolium 
bromide (MTT, Sigma-Aldrich), the medium was replaced with 150 μl of dimethyl 
sulfoxide (DMSO, Riedel-de Haen, Seelze, Germany), each plate was mixed for 10 
min, and the absorbance read at 595 nm. A standard curve was derived from TNF-
α standards, and plasma TNF-α concentrations were calculated from the standard 
curve. All samples were measured twice in separate assays and the respective mean of 
each sample was calculated.
Interleukin-6 and -8
Plasma IL-6 was determined using Quantikine Human IL-6 Immunoassay (R&D 
Systems, Abington, UK) with a detection limit of 0.70 pg/ml in study I, or by using 
Human IL-6 Instant ELISA (Bender MedSystems) immunoassay with a detection 
limit of 0.92 ng/ml in study IV. Plasma IL-8 was determined using Quantikine Hu-
man IL-8 Immunoassay (R&D Systems, Abington, UK), with a detection limit of 10 
pg/ml.
High mobility group box 1 protein 
Western-blotting. Plasma HMGB1 levels were determined by combined heparin-
Sepharose precipitation and Western-blotting methods (Sunden-Cullberg et al. 2005). 
Plasma was added to heparin-Sepharose slurry in PBS. Heparin-Sepharose bound 
proteins were eluted by SDS-PAGE sample buffer, electrophoresed by SDS-PAGE, 
then analysed in a Western-blot probed with chicken anti-HMGB1 IgY (Rouhiainen 
et al. 2004) and peroxidase conjugated anti-chicken IgY (Zymed Laboratories, San 
Francisco, CA, USA). Optical densities of immunoreactive 30 kDa bands were quan-
tified as described (Rouhiainen et al. 2004, Sunden-Cullberg et al. 2005). Normal 
plasma samples containing known amounts of recombinant HMGB1 were analysed 
equally in each gel, and a standard curve was plotted to calculate sample HMGB1 
levels. The sensitivity of the assay was 30 ng/ml.
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Enzyme linked immunosorbent assay. Plasma HMGB1 in donor samples was de-
termined by HMGB1 ELISA Kit II (Shino-Test Corporation, Kanagawa, Japan) im-
munoassay with a detection limit of 1.0 ng/ml. 
Immunohistochemistry. Tissue HMGB1 is mainly in oxidized form (Rouhiainen 
et al. 2007), and therefore a monoclonal antibody recognizing the oxidized form was 
used. Sections of 4 μm were cut from paraffin-embedded liver biopsies, deparaffinized 
in xylen, and rehydrated in a series of graded alcohols. The endogenous peroxidase 
activity was inhibited with 0.1% H2O2 in PBS. The sections were then blocked and 
incubated overnight with anti-HMGB1 (clone KS1, MBL International Woburn, 
MA, USA) in blocking solution. Horseradish peroxidase conjugated anti-mouse IgG 
(GE Healthcare, Little Chalfont Buckinghamshire, UK) was diluted 1:400 in block-
ing buffer and added to the sections. After incubation overnight, the sections were 
washed. Bound antibodies were detected with 1% 3,3′-diaminobenzidine tetrahy-
drochloride hydrate (Sigma-Aldrich) in 0.0003% H2O2 50 mM Tris-HCl-buffer, and 
after color development the sections were washed. Counterstaining was performed 
with Toluidine blue. 
HMGB1 immunostaining was evaluated using a semiquantitative numerical scor-
ing system, with 0 representing completely negative staining, 1 occasional positive, 
2 intermediate, and 3 intense positive staining. Slides were scored independently by 
a pathologist blinded to the blood HMGB1 levels, and also by two members of the 
research group. 
Protein C and activated protein C
Plasma protein C and APC were determined by an enzyme capture assay (Gruber 
and Griffin 1992). An immunoaffinity-purified monoclonal antibody against protein 
C was immobilized in microplates, and the surface was blocked using 1% casein in 
buffer. For the capture of APC and protein C antigen, plasma samples supplemented 
with benzamidine were diluted 1:20 in dilution buffer in the microplate, followed by 
incubation. Then the plates were washed to remove sample constituents and benzami-
dine. The amidolytic activity of the captured APC was measured using chromogenic 
substrate S-2366 (Chromogenix AB, Mölndal, Sweden), with substrate hydrolysis 
measured at 405 nm. Assays were run in duplicate, and a noncommercial plasma pool 
was used as a standard. The sensitivity of the assay was 5 pmol/l, corresponding to 
13% of the normal mean plasma level of APC. 
Total protein C was determined by activating the bound protein C in the immu-
nocaptured samples by a snake venom activator enzyme (Protac, American Diagnos-
tica, Greenwich, Conn, USA). This was followed by measuring the amidolytic activity 
on the chromogenic substrate S-2366. As APC was less than 1% of the total protein 
C, the amidolytic activity observed after Protac activation essentially equaled the to-
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tal protein C value. Protein C antigen was assayed by an Asserachrom Protein C kit 
(Diagnostica Stago, Parsippany, NJ, USA). Assays were run in duplicate, and pooled 
normal human plasma (Precision Biologicals, Dartmouth, Nova Scotia, Canada) was 
used as a standard. 
The results of APC and total protein C were expressed as the percentage of the 
plasma pool defined as 100%. In study II, APC/protein C-ratio was calculated to 
evaluate the magnitude of protein C activation.
STATISTICAL ANALYSIS
Data were analysed with different versions (9.0-12.0.1) of SPSS for Windows (SPSS 
Inc., Chicago, IL, USA). As the sample size was small in study II or when the data 
distribution was skewed according to Kolmogorov Smirnov test in studies I, III, and 
IV, non-parametric tests were used. Time-dependent changes were evaluated by Fried-
man’s test with post hoc Wilcoxon signed rank test with Holm’s correction for multi-
ple comparisons (Holm 1979). To assess changes across the liver, either transhepatic 
gradient (I, II, and IV) or ratio (II, III) was calculated. Transhepatic gradient was 
calculated as the portal vein value subtracted from the hepatic vein or caval effluent 
value, where 0 denotes no change, <0 a decrease, and >0 an increase across the liver. 
Transhepatic ratio was calculated as the hepatic vein or caval effluent value divided by 
the portal vein value, where 1 denotes no change, <1 a decrease, and >1 an increase 
across the liver. The significance was tested using the Wilcoxon signed rank test. Bi-
variate correlations were evaluated by the Spearman rank correlation. The α-level was 
set at 0.05 for all tests. The data are presented as medians with interquartile ranges 





Graft characteristics and the overall outcomes are presented in Table 3. Three patients 
in study III died during the follow up. The causes of death were: multiorgan failure 
(day 5 after transplantation), subarachnoid hemorrhage (day 9), and septic shock (day 
15). Retransplantation was performed ON two patients due to graft necrosis resulting 
from graft size disparity (day 5; study III), hepatic artery thrombosis (2 months; the 
same patient in studies II and III), and persistent graft dysfunction (4 months; study 
III). Postoperative liver function was good in general (Table 3). Graft steatosis and 
CIT did not correlate with postoperative laboratory values (data not shown). 
Table 3. Graft characteristics and outcome during 1-year follow-up 
I II III IVa
Patients, n 30 10 47 20
Cold ischemic time, hrs 5.6 (2.5–14.2) 5.5 (3.2–8.1) 5.5 (2.5–14.2) 5.1 (3.8–10.5)
Anhepatic time, min 54 (40–120) 57 (44–110) 58 (40–120) 56 (35–69)
Graft steatosisb, % 0 (0–80) 0 (0–80) 0 (0–80) 0 (0–30)
Bleeding, l 7.0 (1.9–20.0) 7.2 (1.9–19.8) 5.8 (1.7–20.0) 4.5 (1.5–13.0)
Postoperative liver functionc
ALT, U/l 238 (53–1441) 202 (53–769) 241 (53–10,870) 267 (64–1160)
ALT > 500 U/l, n (%) 7 (23) 2 (20) 12 (26) 5 (25)
ALP, U/l 243 (101–700) 162 (101–307) 287 (101–1407) -
GGT, U/l 201 (44–1260) 184 (44–400) 329 (47–1438) -
Bilirubin, μmol/l 57 (12–420) 41 (20–142) 101 (31–529) 34 (12–156)
PT, % 37 (21–61) 34 (27–50) 42 (21–81) -
Galactose t½, min - - 13 (9.5–30) -
INR - - - 1.5 (1.2–3.6)
Biliary complications, n 5 5 6 0
Vascular complications, n 3 2 3 0
Rejection rate, % 55 80 55 40
Graft survival, % 90 90 87 100
Patient survival, % 93 100 94 100
a Follow-up 3 months in study IV, b Macrovesicular, c During the first postoperative week. 
Data are expressed as median (range).
ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gammaglytamyltransferase; 
PT, prothrombin time; INR, international normalized ratio
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DONOR INFLAMMATORY RESPONSE 
Donor characteristics in study I are shown in Table 2. Donor intensive care was associ-
ated with both an inflammatory response and liver dysfunction. Donors experiencing 
hypotensive events had higher IL-8 levels both in their portal and hepatic venous 
blood as compared to hemodynamically stable donors (see Results in study I). Donor 
ICU stay correlated with donor CRP and IL-6 levels, and with both donor and recipi-
ent GGT levels (Table 4). On the other hand, donor GGT, correlated with recipient 
peak GGT, ALP, and bilirubin levels (Table 4). 
Cytokine and adhesion molecule expression levels are presented in Table 5. In 17 
out of 29 donors, hepatic IL-8 release was observed immediately before graft per-
fusion, i.e. IL-8 levels were higher in hepatic venous blood than in portal blood (posi-
Table 4. Correlations between donor and recipient variables
R P
Donor ICU stay Donor CRP 0.472 0.013
Donor IL-6 0.419 0.026
Donor GGT 0.478 0.016
Recipient GGT 0.432 0.019
Donor GGT Recipient GGT 0.633 0.001
Recipient ALP 0.422 0.035
Recipient bilirubin 0.654 <0.001
ICU = intensive care unit, CRP = C-reactive protein, GGT = gamma-glutamyl transferase,             
ALP = alkaline phosphatase. R,P from Spearman rank correlation.
Table 5. Donor inflammatory response during liver procurement
Baseline Portal vein Hepatic vein
IL-6 (ng/mL) 235 (61–614)a 636 (228–1875) 490 (127–1611)
IL-8 (ng/mL) 31 (28–34)b 45 (36–61) 47 (39–61)
Soluble ICAM-1 (ng/mL) 219 (174–234)b 160 (145–184) 158 (142–176)
PMN CD11b (RFU) 485 (256–673) 387 (264–645) 487 (349–598)
PMN L-selectin (RFU) 93 (76–142)c 149 (84–171) 110 (76–158)
Data are expressed as median (interquartile range). PMN = neutrophil, RFU = relative fluorescence unit 
a P < 0.01, b P < 0.001, c P < 0.05 baseline vs. portal vein; Wilcoxon signed rank test
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tive transhepatic gradient). Similar subgroups could be created according to hepatic 
IL-6 release and neutrophil CD11b expression, but only hepatic IL-8 release was as-
sociated with liver dysfunction. Before organ procurement, GGT levels were elevated 
in donors in whom the transhepatic IL-8 gradients were subsequently positive (Figure 
6). After transplantation, both ALP and bilirubin levels were higher in those recipients 
who received a graft with a positive transhepatic IL-8 gradient (Figure 6). A similar 
trend was found for ALT and GGT levels (Figure 6). Five recipients suffered from 
postoperative biliary complications (anastomotic strictures or leakage). Their occur-
rence was not associated with hepatic cytokine release in the donor.
INFLAMMATORY RESPONSE DURING LIVER TRANSPLANTATION 
Systemic inflammation
In studies II and III, CD11b and L-selectin expression in the circulating neutrophils 
and monocytes increased throughout surgery (Table 6; see also Table 2 in study III). 
In study IV, TNF-α levels in systemic circulation decreased before reperfusion, but 
Table 5. Donor inflammatory response during liver procurement
Baseline Portal vein Hepatic vein
IL-6 (ng/mL) 235 (61–614)a 636 (228–1875) 490 (127–1611)
IL-8 (ng/mL) 31 (28–34)b 45 (36–61) 47 (39–61)
Soluble ICAM-1 (ng/mL) 219 (174–234)b 160 (145–184) 158 (142–176)
PMN CD11b (RFU) 485 (256–673) 387 (264–645) 487 (349–598)
PMN L-selectin (RFU) 93 (76–142)c 149 (84–171) 110 (76–158)
Data are expressed as median (interquartile range). PMN = neutrophil, RFU = relative fluorescence unit 
a P < 0.01, b P < 0.001, c P < 0.05 baseline vs. portal vein; Wilcoxon signed rank test
Results
Figure 6. Graft IL-8 release and donor and recipient liver function. 
Data are medians with IQR. Transhepatic gradient was calculated as portal vein value subtract-
ed from hepatic vein value. Positive (pos) gradient denotes efflux from the liver, and negative 
(neg) gradient denotes influx into the liver. * P < 0.05, ** P < 0.01 pos vs. neg. 
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returned close to the preoperative levels after reperfusion (Figure 7). In contrast to de-
creasing TNF-α levels, IL-6 levels had already increased during the recipient hepatec-
tomy. After reperfusion, IL-6 levels remained high throughout surgery, but decreased 
quickly postoperatively (Figure 7). Unlike TNF-α and IL-6, HMGB1 was undetect-
able in the systemic circulation before reperfusion. However, HMGB1 levels rapidly 
increased upon reperfusion and peaked at 10 min after portal vein declamping. There-
after, HMGB1 levels declined, and at 8 h after reperfusion it was only detectable in 
six patients (Figure 8).
Table 6. Neutrophil and monocyte adhesion molecule expression during surgery
0 A1 A2 R1 R2 R3
CD11b Expression, RFU
Neutrophil 160 (57–443) 244 (64–422) 237 (128–504) 357 (149–470) 309 (168–478) 331 (181–595)
Monocyte 201 (129–556) 216 (93–3286) 198 (108–662) 194 (146–2274) 370 (185–2860) 254 (154–781)
L-selectin Expression, RFU
Neutrophil 159 (79–305) 206 (100–301) 199 (158–380)a 190 (158–380)a 214 (166–342)a 211 (164–361)a
Monocyte 178 (59–285) 295 (167–517)a 348 (162–469)a 275 (154–543)a 266 (174–605)a 347 (201–461)a
Time points: before surgery (0), before anhepatic period (A1), before reperfusion (A2), during initial reperfusion (R1), 5 min after portal 
vein declamping (R2), 10 min after hepatic artery declamping (R3). RFU, relative fluorescence unit. ap < 0.05 vs. 0 
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Neutrophil 224 (28–502) 364 (29–1048) 1.5 (0.2–4.8)a 235 (28–548) 306 (27–886) 1.2 (0.1–2.5)a
Monocyte 194 (22–2274) 724 (33–2190) 3.0 (0.2–10.0)a 345 (26–3885) 690 (64–2776) 1.6 (0.5–9.8)a
L-selectin expression, RFU
Neutrophil 243 (83–620) 205 (100–441) 0.9 (0.4–1.8)a 255 (86–633) 249 (87–628) 0.9 (0.5–1.8)a
Monocyte 311 (123–764) 235 (66–568) 0.8 (0.3–1.6)a 261 (110–605) 230 (105–589) 0.9 (0.4–1.4)a
a all P < 0.001, graft caval effluent or hepatic vein vs. porta. 
Time points: R1 = initial reperfusion, R2 = 5 min after portal vein declamping. RFU = relative fluorescence unit
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Hepatic inflammation
During reperfusion, hepatic neutrophil and monocyte activation, as indicated by 
CD11b upregulation with concomitant L-selectin shedding across the hepatic circu-
lation, was evident (Table 7; see also Results in study II). Graft neutrophil sequestra-
tion occurred during initial reperfusion and at 5 min after portal vein declamping (see 
Results in studies II and III), whereas graft monocyte entrapment was not detected.
Results
Figure 7. Plasma TNF-α, and IL-6 levels in systemic circulation during and after transplanta-
tion. Time points: before surgery (A0), immediately before initial reperfusion (A1), 10 min 
after portal vein declamping (A2), and 10 min after hepatic artery declamping (A3), and at 8, 
24, and 48 hours after reperfusion (8h, 24h, and 48h, respectively). Data are as medians with 
IQR. *P<0.05, **P<0.01, ***P<0.001 vs. before surgery.
Figure 8. Plasma HMGB1 levels in 
systemic circulation during and after 
transplantation. Time points and de-
tailed explanations, see the legend in 
Figure 7. *P<0.05, ***P<0.001 vs. be-
fore surgery.











Neutrophil 224 (28–502) 364 (29–1048) 1.5 (0.2–4.8)a 235 (28–548) 306 (27–886) 1.2 (0.1–2.5)a
Monocyte 194 (22–2274) 724 (33–2190) 3.0 (0.2–10.0)a 345 (26–3885) 690 (64–2776) 1.6 (0.5–9.8)a
L-selectin expression, RFU
Neutrophil 243 (83–620) 205 (100–441) 0.9 (0.4–1.8)a 255 (86–633) 249 (87–628) 0.9 (0.5–1.8)a
Monocyte 311 (123–764) 235 (66–568) 0.8 (0.3–1.6)a 261 (110–605) 230 (105–589) 0.9 (0.4–1.4)a
a all P < 0.001, graft caval effluent or hepatic vein vs. porta. 
Time points: R1 = initial reperfusion, R2 = 5 min after portal vein declamping. RFU = relative fluorescence unit
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In study IV, TNF-α levels were comparable across the hepatic circulation at all 
time points (Table 8). During initial reperfusion, graft IL-6 uptake occurred, as IL-6 
levels were higher in portal venous blood than in the caval effluent. A few moments 
later, at 10 min after portal vein declamping, a slight graft IL-6 release was evident 
(Table 8). 
During initial reperfusion, HMGB1 levels (study IV) were undetected in the por-
tal venous blood. In contrast, HMGB1 levels were remarkably high in the caval efflu-
ent, indicating substantial graft HMGB1 release. After reperfusion, ongoing HMGB1 
release from the graft was demonstrated as HMGB1 levels remained significantly 
higher in the hepatic venous blood than in the portal venous blood (Figure 9). He-
patic HMGB1 expression increased during graft preservation and reperfusion in the 
tissue biopsies. Moreover, HMGB1 was predominantly expressed in the cytoplasm 
of hepatocytes located close to the central veins (Figure 3 in study IV), with only oc-
casional neutrophil staining. The sinusoidal endothelium and portal structures were 
HMGB1 negative. The HMGB1 expression in biopsies taken both before and after 
reperfusion correlated with HMGB1 levels in the caval effluent.
Table 8. TNF-α and IL-6 levels during reperfusion
Initial reperfusion 10 min portal vein declamping 10 min hepatic artery declamping
A P H A P H A P H
TNF-α, 
pg/mL
1.7 (1.0–4.8) 1.9 (0.7–4.9) 1.7 (0.6–3.2) 1.3 (0.5–3.3) 1.2 (0.5–2.1)a 1.3 (0.2–4.5) 1.8 (1.0–6.9) 2.1 (0.7–7.3) 2.5 (1.2–6.9)
IL-6, ng/mL 147 (86–337) 153 (81–361) 135 (60–248)b 124 (85–184) 122 (77–264) 121 (67–222)b 96 (86–224) 113 (80–242) 97 (58–222)
Data are expressed as median (interquartile range). A, systemic artery; P, portal vein; H, hepatic vein (caval effluent at initial reperfusion)
a P < 0.05, systemic artery vs. portal vein; b P < 0.05, portal vs. hepatic vein.
Results
Figure 9. Plasma HMGB1 levels 
during reperfusion. A, systemic 
artery; P, portal vein; H, hepatic 
vein (caval effluent during initial 
reperfusion). Time points and de-
tailed explanations, see the legend 
in Figure 7. **P<0.01, ***P<0.001 
portal vs. hepatic vein. ##P<0.01, 
###P<0.001 vs. previous time point
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Graft function
In contrast to those of other cytokines or markers of neutrophil and monocyte activa-
tion (data not shown), HMGB1 levels were associated with subsequent graft function. 
At 10 min after hepatic artery declamping, HMGB1 levels in both the systemic arte-
rial and hepatic venous blood correlated with peak postoperative ALT levels (Figure 
10). Further, graft steatosis correlated with HMGB1 levels in hepatic venous blood at 
10 min after hepatic artery declamping (Figure 10).
Results
Figure 10. Correlations between 
HMGB1 levels, ALT, and graft stea-
tosis. For HMGB1, levels represent 
those measured from radial arterial 
and hepatic venous blood at 10 min 
after hepatic artery declamping.
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PROTEIN C – ACTIVATED PROTEIN C PATHWAY 
IN LIVER TRANSPLANTATION
Before surgery, preoperative protein C levels were low, and decreased slightly during 
surgery in studies II and III. In contrast, APC levels increased constantly during sur-
gery, and peaked at 5 min after portal vein declamping (Figure 11; see also Figure 1 
in study III). Calculated APC/protein C-ratio in study II increased during surgery, in-
dicating an increased APC formation despite decreasing protein C levels (Figure 11). 
The postoperative protein C levels increased markedly with a concomitant decrease in 
APC levels close to those observed preoperatively (Figure 11). 
Protein C levels were lower in the caval effluent as compared to portal venous 
blood during initial reperfusion , but not thereafter, indicating substantial graft pro-
tein C uptake (Figure 12; see also Figure 2 in study II). In study III, graft protein C 
Results
Figure 11. Plasma activated protein C 
(APC), and protein C (PC) levels, and 
APC/PC ratio during and after trans-
plantation. Time points: before sur-
gery (0), before anhepatic period (A1), 
before reperfusion (A2), during initial 
reperfusion (R1), 5 min after portal 
vein declamping (R2), 10 min after 
hepatic artery declamping (R3). P1-P6 




Figure 12. Protein C uptake within the liver graft 
during reperfusion. Transhepatic ratios of APC 
and protein C. Transhepatic ratio was calculated 
as hepatic venous or graft caval effluent value di-
vided by portal venous value. Time points: during 
initial reperfusion (R1), 5 min after portal vein 
declamping (R2). Values for the whole study pop-
ulation are expressed as box-whisker plots. Boxes 
indicate median with IQR. Vertical bars denote 
the range. P value is given for caval effluent vs. 
portal vein.
Figure 13. Correlation between tran-
shepatic protein C ratio and transhe-
patic neutrophil (PMN) and mono-
cyte (MO) CD11b ratio during initial 
reperfusion. Transhepatic ratio was 
calculated as graft caval effluent value 
divided by portal venous value.
entrapment occurred in all but two patients (n=45). Despite graft protein C uptake, 
APC levels were comparable across the hepatic circulation, suggesting that APC was 
not released concomitantly from the graft with protein C uptake (Figure 12). 
Transhepatic protein C ratio (III) correlated with neutrophil and monocyte 
CD11b expression levels. This indicated that graft protein C uptake was associated 





The sample sizes of each study were mainly constrained by the availability of patients, 
i.e. the annual liver transplantation rate in HUCH that varies from 40 to 60 per year. 
All studies comprise consecutive patients. Nevertheless, the sample sizes are similar or 
even large compared to previous observational studies on the inflammatory response 
in clinical liver transplantation. Further, in study II with only 10 patients, a similar 
trend in study parameters were observed in all patients, implying a true biological 
phenomenon. 
The patient population was heterogenous because both patients with ALF and 
those with chronic liver disease were included. This may have influenced the results 
to a certain extent, as ALF is characterized by systemic inflammatory response with 
elevated plasma cytokine levels (Muto et al. 1988, Sekiyama et al. 1994). Further, in 
experimental liver transplantation, Wang et al. (2001) demonstrated that the proin-
flammatory state of the recipient potentiates I/R injury. On the other hand, the num-
bers of ALF patients included in these studies were small (Table 1), and any resulting 
strong influence on the results is therefore unlikely. 
Immunosuppression varied in studies III and IV, with either cyclosporine or tac-
rolimus based regimens being used. In addition to inhibiting T-cell proliferation and 
activation, tacrolimus and cyclosporine have similar effects on the innate immune 
system. These immunosuppressants in vitro inhibit Kupffer cell activation (Tojimbara 
et al. 1996) in addition to downregulating hepatic TNF-α expression and inhibit neu-
trophil tissue infiltration in experimental liver I/R injury (Suzuki et al. 1993, Ishii et 
al. 1994, Matsuda et al. 1998). Thus, presumably the effect of immunosuppression on 
the inflammatory response was concordant regardless of the drug used. Although the 
effect of immunosuppression was not evaluated in study III, in contrast there was no 
difference in cytokine levels between patients administered with either cyclosporine 
or tacrolimus in study IV. 
Systemic blood samples during reperfusion were not taken in studies II and III, 
instead only blood samples from the portal and hepatic veins were collected. During 
portal venous clamping (the anhepatic phase) the splanchnic region suffers from stag-
nant blood flow and hypoperfusion, followed by reperfusion upon restoration of the 
portal blood flow. In an experimental setting, portal vein ligation induces activation 
of coagulation cascades in the intestinal circulation (Nakao and Tagaki 1993). On the 
other hand, reperfusion in clinical liver transplantation is associated with inflamma-
tory activation in the splanchnic region (Pesonen et al. 2000). It is possible that pro-
tein C and/or APC are utilized in anticoagulant and anti-inflammatory activity within 
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the splanchnic microvascular beds during liver reperfusion. Therefore, this may have 
influenced protein C and APC levels in the portal venous blood, and thus the levels 
of these substances within the liver. Although protein C and APC levels in systemic 
circulation might have been higher than those in the portal venous blood, the main 
focuses of studies II and III were on the liver, and the study setting depicts the actual 
situation within the liver during reperfusion.
DONOR INFLAMMATORY RESPONSE
Plasma HMGB1 levels in study IV were already slightly elevated in organ donors be-
fore graft procurement. This plausible reflects the systemic proinflammatory response 
induced by brain death (Palombo et al. 1994, Strangl et al. 2001, Weiss et al. 2007, 
Murugan et al. 2008). 
Hepatic IL-8 release observed in study I reflects the end result of several contribut-
ing factors. In human organ donors, liver cytokine expression is already upregulated 
at the beginning of donor laparotomy (Kuecuek et al. 2005, Weiss et al. 2006), sug-
gesting that circumstances before organ procurement influence graft quality. Both 
brain death and the following donor intensive care can contribute to inflammatory 
responses in the liver. In a clinical setting, it is impossible to investigate the effects of 
brain death independently of donor intensive care. However, in experimental models, 
brain death alone leads to enhanced cytokine expression in Kupffer cells, hepatocytes, 
and sinusoidal endothelial cells (Takada et al. 1998, Okamoto et al. 2000). Nonethe-
less, donor intensive care seems to aggravate the hepatic inflammation already pres-
ent. Jassem et al. (2003) reported that donor infection, mechanical ventilation, and 
vasoactive support were associated with the activation of inflammatory cascades in the 
liver. Moreover, organ procurement surgery itself possibly activates directly through 
the Kupffer cell activation (Schemmer et al. 1998), hepatic cytokine expression dur-
ing donor laparotomy (Weiss et al. 2006). In the current study, the relative impact of 
brain death, intensive care, and surgery on the graft IL-8 release could not be deter-
mined. Even so, blood samples across the hepatic circulation were collected immedi-
ately before graft perfusion, thereby reflecting the cumulative effects of these factors 
upon graft viability.
Hepatic IL-8 release during graft retrieval correlated with higher recipient ALP 
and bilirubin levels during the first postoperative week. This was accompanied by 
a trend towards higher ALT and GGT levels. These data suggest that donor inflam-
matory response predisposes to liver dysfunction after transplantation. Weiss et al. 
(2006) demonstrated more intense inflammatory activation and I/R injury (defined 
as elevated transaminase levels) in grafts from brain dead donors, compared to those 
from living donors. In this study, instead of the immediate hepatocellular damage af-
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ter reperfusion, hepatic IL-8 release during procurement was associated with apparent 
biliary dysfunction a few days after transplantation. The biliary epithelium is sensitive 
to cold ischemia and reoxygenation (Noack et al. 1993). In addition, long CIT is also 
associated with biliary complications after transplantation (Sanchez-Urdazpal et al. 
1992). Interestingly, hepatic IL-8 release in the donor was not only associated with 
recipient liver function, but also with elevated donor GGT levels. Moreover, donor 
GGT levels correlated with recipient postoperative GGT, ALP, and bilirubin levels. 
These findings suggest that damage to the biliary epithelium may already have begun 
before graft preservation. 
Systemic inflammation, hemodynamic instability, and mechanical ventilation are 
known risk factors for liver dysfunction in patients in intensive care (Brienza et al. 
2006). In addition to changes caused by brain death, donor intensive care may con-
tribute to graft quality. Indeed, a prolonged donor ICU stay is reported to be a risk 
factor for poor graft function and outcome (Briceno et al. 2002, Cuende et al. 2005). 
In this study, even short donor ICU stay (median one day) correlated with both el-
evated GGT levels in the donor and the recipient. These data underline that factors 
related to donor intensive care, although essential for organ donation, can also con-
tribute to liver dysfunction subsequent to tranplantation. 
INFLAMMATORY RESPONSE DURING LIVER TRANSPLANTATION 
Systemic inflammation
During recipient hepatectomy, surgical stress had already induced systemic inflamma-
tion. Both CD11b and L-selectin expression on neutrophils and monocytes increased 
in studies II and III, indicating the activation of circulating phagocytes (Kishimoto 
et al. 1989) and mobilization of new cells from the bone marrow (van Eeden et al. 
1995). Further, IL-6 levels in systemic circulation increased during hepatectomy, and 
remained high throughout surgery in study IV. 
After transplantation, both IL-6 and HMGB1 levels decreased rapidly and were 
detectable in only a few patients at 8 h after reperfusion in study IV. In clinical sepsis, 
elevated IL-6 and HMGB1 levels persist for days, indicating ongoing inflammation 
(Sunden-Cullberg et al. 2005). The rapidly declining IL-6 and HMGB1 levels ob-
served in this study argue against prolonged systemic inflammatory response after 
liver transplantation. However, in this study patient recovery was uneventful in most 
cases and graft function remained good. Possibly, elevated IL-6 and HMGB1 levels 
could be detected in the event of postoperative complications. Indeed, Mueller et al. 
(1996) reported that prolonged elevation of IL-6 postoperative levels seems to indi-




During initial reperfusion, pronounced hepatic neutrophil and monocyte activation 
and subsequent sequestration became evident, as manisfested by a transhepatic in-
crease in CD11b expression and a decrease in cell counts in studies II and III. Earlier, 
it was suggested that phagocytes have no role in the initial liver I/R injury as hepatic 
phagocyte infiltration was delayed for up to several hours after reperfusion (Jaeschke 
et al. 1990). However, these results were from experimental studies on liver I/R injury 
after long warm ischemic times. The data presented in this thesis corroborate previ-
ous studies, both experimental and clinical, which indicated that, after cold ischemia, 
phagocyte activation occurs immediately after restoration of blood flow (Shibuya et al. 
1997, Pesonen et al. 2000, Kataoka et al. 2002).
As the liver is the main site for IL-6 clearance in the body (Castell et al. 1988), it 
is not surprising that IL-6 uptake by the liver occurred during initial reperfusion in 
study IV. This finding is in accordance with previous studies by our group (Pesonen et 
al. 2000). Although speculation, this IL-6 uptake may reflect IL-6 utilization in anti-
inflammatory processes. IL-6 treatment reduces I/R injury after warm liver ischemia 
(Camargo et al. 1997), and endogenous IL-6 regulates hepatocyte apoptosis and in-
duces liver regeneration (Clavien et al. 2003). 
Extensive hepatic HMGB1 release occurred during initial reperfusion in study 
IV. Afterwards, HMGB1 levels remained significantly higher in hepatic venous blood 
than they did in portal blood, indicating ongoing HMGB1 release from the graft. 
However, both absolute HMGB1 levels in hepatic venous blood and the calculated 
transhepatic gradient decreased after initial reperfusion. Therefore, the HMGB1 ef-
flux appears to reflect a wash-out of HMGB1 released as early as during graft pres-
ervation and/or immediately during initial reperfusion, i.e. graft flushing with portal 
venous blood instead of progressive inflammatory activation. 
HMGB1 has been regarded as a proinflammatory cytokine that is actively secreted 
by neutrophils, monocytes, and macrophages (Wang et al. 1999, Lotze and Tracey 
2005). Although transhepatic neutrophil and monocyte activation was evident dur-
ing reperfusion, hepatocytes appear to be the main source of HMGB1 in clinical 
liver transplantation. Moreover, HMGB1 expression in hepatocytes significantly in-
creased during graft preservation and reperfusion, whereas neutrophils infiltrating the 
liver, portal structures, and the sinusoidal endothelium had no or only weak HMGB1 
staining. In addition to active secretion from the innate immune cells, HMGB1 is 
released passively from damaged cells (Scaffidi et al. 2002). Although hepatocytes are 
relatively resistant to cold preservation, they are readily damaged by the subsequent 
rewarming ischemia (Vajdová et al. 2000). Further, despite maintaining cellular in-
tegrity, hepatocyte HMGB1 expression increases quickly after noxious stimuli (Sass 
et al. 2002, Tsung et al. 2005a, Tsung et al. 2007). In this study, HMGB1 was pre-
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dominantly expressed in hepatocytes located close to the central veins, i.e. in areas 
most susceptible to ischemic injury. Thus, HMGB1 appears to originate mainly from 
hepatocytes, either through active secretion from ischemic cells or passive release from 
those that are necrotic.
HMGB1 stimulates phagocytes to release proinflammatory cytokines including 
TNF-α, IL-1β, IL-6, and IL-8 (Andersson et al. 2000, Park et al. 2003). Interestigly, 
HMGB1 levels did not correlate with those of TNF-α and IL-6. Rouhiainen et al. 
(2007) have demonstrated that HMGB1 itself exhibits only weak proinflammatory 
activity, whereas binding to bacterial lipid components strengthens the proinflam-
matory effects of HMGB1 (Rouhiainen et al. 2007, Sha et al. 2008). Although li 
ver transplantation is known to induce systemic endotoxemia, LPS is not uniformly 
present in all patients (Hamilton et al. 1993). Indeed, in the absence of stimulating 
cofactors, the proinflammatory effects of HMGB1 may be of minor significance in 
clinical liver I/R injury. 
Graft function
Surprisingly, neither hepatic phagocyte activation and sequestration, nor cytokine lev-
els correlated with postoperative graft function (II, III, and IV). Hepatic neutrophil 
activation during reperfusion in particular was very strong compared to that in other 
organs. In clinical kidney transplantion, even modest kidney neutrophil sequestration 
predicts delayed graft function (Turunen et al. 2004). However, despite early infiltra-
tion into the graft after reperfusion in experimental liver transplantation, neutrophils 
may not contribute to hepatocellular injury, if the cold preservation period remains 
short (Kataoka et al. 2002). In other words, a short CIT may protect the liver from 
neutrophil-mediated graft injury. In our centre, CIT is generally very short (median 
5 h 27 min in study III). Although undeniable as a phenomenon, the clinical signifi-
cance of hepatic neutrophil activation may be questioned in human liver transplanta-
tion, at least after a short graft cold preservation.
To reiterate, HMGB1 was expressed in hepatocytes after reperfusion, whereas in-
nate immune cells did not seem to contribute to HMGB1 release in study IV. Ac-
cordingly, HMGB1 primarily appears as a marker of hepatocellular injury. Indeed, 
sustained hepatic HMGB1 release was associated with postoperative graft function. 
Hepatic venous HMGB1 levels measured at 10 min after hepatic artery declamping 
(approximately 45 min after initial reperfusion) correlated both with graft steatosis 
and peak postoperative ALT levels. The correlation between HMGB1 release and graft 
steatosis suggests that even mild steatosis is associated with pronounced injury dur-
ing preservation and reperfusion. Further, graft HMGB1 outflow was associated with 
higher peak postoperative ALT levels, supporting the role of HMGB1 as an indicator 
of hepatocellular injury. 
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PROTEIN C – ACTIVATED PROTEIN C PATHWAY 
IN LIVER TRANSPLANTATION 
Acquired protein C deficiency contributes to postoperative thrombotic complications 
after liver transplantation (Harper et al. 1988). In this study, as expected, protein C 
levels were low preoperatively and decreased during transplantation in patients with 
liver insufficiency. However, patients were able to maintain normal to supranormal 
APC levels throughout surgery. This indicates that, despite protein C deficiency, pro-
tein C activation is enhanced to preserve coagulation homeostasis. Further, protein C 
levels normalize within a few days after a successful transplantation, which indicates 
normal synthetic function of the liver. These may be the key factors preventing throm-
botic complications related to protein C deficiency during initial graft reperfusion. In 
this study, there was no association between protein C or APC levels and thrombotic 
complications. Three patients developed postoperative HAT, possibly due to surgical 
problems encountered in the arterial anastomosis (Settmacher et al. 2000).
Reperfusion of the liver creates an environment that favours protein C activation. 
TM is already upregulated on the endothelial surface as early as during graft preser-
vation (Suehiro et al. 1997), and hepatic thrombin generation occurs rapidly during 
initial reperfusion (Himmelreich et al. 1994). Although not indispensable to protein 
C activation by thrombin-TM complex, EPCR is upregulated on the endothelium in 
response to thrombin formation (Gu et al. 2000). This probably enhances protein C 
activation to APC. In this study, substantial graft protein C uptake occurred within 
the hepatic circulation during initial reperfusion without a corresponding outflow 
of APC from the graft. If protein C had been simply activated without concomitant 
APC utilization, a significant APC release from the liver would be expected. Thus 
the lack of APC release suggests a demand for APC within the graft during initial 
reperfusion. 
During initial reperfusion, extensive phagocyte activation and trapping in the liver 
concomitantly with graft protein C uptake became evident. Further, enhanced protein 
C consumption was associated with reduced hepatic phagocyte activation. These data 
suggest involvement of the protein C pathway in regulation of the anti-inflammatory 
processes in vivo. Therefore a direct inhibitory effect of protein C, on phagocytes is 
possible without preceding activation (Sturn et al. 2003). Alternatively, protein C 
uptake can non-exclusively result in significant intrahepatic activation and subsequent 
APC involvement in anticoagulant and anti-inflammatory activity.
Several molecular and cellular mechanisms underlie the cytoprotective actions of 
the protein C pathway. APC suppresses the transcription factor NF-κB expression 
and functional activity, in addition to inhibiting transcription factors of the activator 
protein-1 (AP-1) family (Joyce et al. 2001). Thus APC inhibits cytokine signalling 
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and adhesion molecule expression in both the innate immune and endothelial cells. 
In this study, the described phenomena occurred within only a few minutes during 
initial reperfusion. Therefore, mechanisms involving gene transcription and protein 
synthesis are unlikely to explain these findings. 
The association between protein C entrapment and reduced phagocyte CD11b 
expression suggests that mechanisms involved in cell adhesion are important in I/
R injury. In vitro, protein C pathway modulates leukocyte recruitment into sites of 
inflammation. APC inhibits phagocyte migration toward chemoattractants (Sturn 
et al. 2003, Nick et al. 2005, Galley et al. 2008). It may also inhibit both selectin 
and integrin mediated phagocyte adhesion. Moreover, APC impairs selectin-medi-
ated leukocyte attachment to the endothelium (Grinnell et al. 1994). Soluble EPCR 
also binds to neutrophils via CD11b and may further interfere with phagocyte-en-
dothelial interaction (Kurosawa et al. 2000). In experimental liver I/R injury, APC 
decreases neutrophil accumulation in the postischemic tissue (Yamaguchi et al. 1997, 
Kuriyama et al. 2008). This effect is likely to be mediated through cell adhesion, as 
APC has been observed to reduce ICAM-1 expression on the endothelium and tis-
sue accumulation of CD11b positive neutrophils in other experimental I/R-injury 
models (Shibata et al. 2001). Moreover, previous studies on clinical I/R injury sug-
gest that APC partly exerts its anti-inflammatory activities through the inhibition of 
neutrophil adhesion. In coronary bypass surgery, postischemic protein C activation 
is associated with decreased cardiac neutrophil accumulation (Petäjä et al. 2001). By 
comparison, in kidney transplantation, APC utilization within the graft is associated 
with decreased neutrophil L-selectin shedding and CD11b upregulation, in addition 
to reduced lactoferrin release (Turunen et al. 2005). Taken together, the results in the 
present study corroborate previous findings, and suggest that anti-inflammatory prop-
erties of protein C pathway in clinical liver transplantation are related to decreased 
neutrophil and monocyte activation in addition to reduced potential for endothelial 
adhesion.
FUTURE CONSIDERATIONS
In liver transplantation, both clinical and experimental, research has been confined to 
graft preservation and reperfusion, and few studies on the organ donors per se exist. 
However, organ shortage is becoming a critical problem, which has lead to the accept-
ance of grafts obtained from “extended criteria” donors. Therefore, instead of focus-
ing studies on merely I/R injury, the emphasis should be directed onto the donor. 
Brain death itself has been shown to activate inflammatory responses in donor organs 
(Pratschke et al. 1999). Further, in a clinical setting the inevitable intensive care of the 
donor before organ procurement may also affect graft quality. In this thesis, hepatic 
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inflammatory activation already occurred during graft procurement and was associ-
ated with subsequent graft dysfunction (I). Accordingly, influencing the inflamma-
tory responses in the donor appears tempting. In a preliminary clinical study, Kuecuek 
et al. (2005) reported that continuous steroid infusion after a loading dose leads to 
decreased hepatic cytokine expression in human brain dead liver donors, although the 
effects on subsequent graft function were not reported. Probably, limiting inflamma-
tion in the donor would result in better graft function. In the future, after resolving 
the ethical questions related to pre-emptive treatment of the donor, anti-inflamma-
tory interventions may well become routine.  
The clinical risk factors for graft dysfunction are quite well defined (Nissen and 
Colquhoun 2005). However, in individual patients these risk factors may not accu-
rately predict the outcome of transplantation. Identifying the patients at risk of PDF 
or PNF during surgery would help the optimization of the postoperative treatment 
of these patients and, possibly avoid complications. In this thesis (IV), HMGB1 in-
dicated hepatocellular damage. After arterial reperfusion, HMGB1 levels measured 
in the systemic circulation correlated with peak postoperative ALT levels. HMGB1 
might therefore be useful as an early marker of graft dysfunction, although a study 
with sufficient statistical power is needed to evaluate the prognostic value of HMGB1 
in liver transplantation. If grafts developing primary dysfunction could be identified 
as early as during reperfusion, possible interventions could be directed at those recipi-
ents in a timely fashion. 
As I/R injury can influence subsequent graft function, interventions based on 
physiological anti-inflammatory agents would be useful. A growing body of evidence 
supports the anti-inflammatory effects of the protein C pathway in I/R injury (Levi 
et al. 2004). In rats, APC treatment has multiple cytoprotective effects that have been 
reported to be mediated through both anti-inflammatory and anticoagulant functions 
in warm hepatic I/R injury (Kuriyama et al. 2008). In this thesis, a rapid and marked 
hepatic protein C uptake occurred without a concomitant APC release in studies 
II and III. A shortage of APC relative to its physiologic demand and/or APC inde-
pendent anti-inflammatory action of protein C during reperfusion may explain the 
phenomenon. Both previous experimental research and the current results, provide a 
rationale for future clinical intervention studies with protein C or APC in liver I/R 
injury. As the most marked changes were observed during initial reperfusion, i.e. dur-
ing graft flushing with portal venous blood, supplementation during this period seems 
feasible. Moreover, the systemic effects on the coagulation system could be avoided, as 




The following conclusions can be drawn from these studies:
1. Even a short donor ICU length of stay correlated with elevated GGT levels in 
the donor. Donor livers with even a subtle dysfunction in turn exhibited IL-8 release 
during graft procurement and subsequent graft, particularly biliary, dysfunction in 
the recipient. These findings suggest that the inflammatory response related to brain 
death and the care of the donor influenced subsequent graft function in the liver 
recipient (I).
2. Despite low protein C levels related to liver insufficiency, patients were able to 
maintain coagulation homeostasis through enhanced protein C activation, as indi-
cated by the normal to supranormal APC levels observed. Protein C levels normalized 
within a few days after a successful liver transplantation. During initial reperfusion, 
a marked hepatic protein C uptake was evident without a concomitant APC release 
from the graft. Further, enhanced graft protein C uptake was associated with weaker 
hepatic neutrophil and monocyte activation. These data suggest that APC is utilized 
within the graft, at least partly, in anti-inflammatory activity (II,III). 
3. HMGB1 in the systemic circulation originated from the graft. After an un-
eventful liver transplantation, HMGB1 levels normalized rapidly, which suggested 
that a prolonged inflammatory response did not occur. During reperfusion, a substan-
tial and continuous HMGB1 release from the graft occurred. Immunohistochemistry 
revealed that hepatocytes, particularly those located close to the central veins were the 
primary source for HMGB1. Graft HMGB1 release correlated with both steatosis and 
peak postoperative ALT. HMGB1 therefore appears to be a marker of hepatocellular 
injury, and might have a prognostic value in clinical liver transplantation (IV).
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